

23-1-2017

**A Short History Of The 5-HT<sub>2c</sub> Receptor:**

**From The Choroid Plexus To Depression, Obesity And Addiction Treatment**

Jose M. Palacios<sup>1</sup>, Angel Pazos<sup>2</sup>, and Daniel Hoyer<sup>3,4,5</sup>

1: Frontera Biotechnology SL, Barcelona, Spain.

2: Universidad de Cantabria, Instituto de Biomedicina y Biotecnología de Cantabria, CSIC-UC-IDICAN, CIBERSAM, Santander, Spain.

3: Department of Pharmacology and Therapeutics, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria 3010, Australia.

4: The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, 30 Royal Parade, Parkville, Victoria 3052, Australia.

5: Department of Chemical Physiology, The Scripps Research Institute, 10550 N. Torrey Pines Road, La Jolla, CA 92037, USA.

\*Address correspondence and reprint requests to: [d.hoyer@unimelb.edu.au](mailto:d.hoyer@unimelb.edu.au)

## ABSTRACT

This paper is a personal account on the discovery and characterization of the 5-HT<sub>2C</sub> receptor (first known as the 5-HT<sub>1C</sub> receptor) over 30 years ago and how it translated into a number of unsuspected features for a G-protein coupled receptor (GPCR) and a diversity of clinical applications. The 5-HT<sub>2C</sub> receptor is one of the most intriguing members of the GPCR superfamily. Initially referred to as 5-HT<sub>1C</sub>R, the 5-HT<sub>2C</sub>R was discovered while studying the pharmacological features and the distribution of [<sup>3</sup>H]mesulergine labelled sites, primarily in the brain using radioligand binding and slice autoradiography. Mesulergine (SDZ CU-085), was at the time best defined as a ligand with serotonergic and dopaminergic properties. Autoradiographic studies showed remarkably strong [<sup>3</sup>H]mesulergine-labelling to the rat choroid plexus. [<sup>3</sup>H]mesulergine-labelled sites had pharmacological properties different from at the time known or purported 5-HT receptors. In spite of similarities with 5-HT<sub>2</sub> binding, the new binding site was called 5-HT<sub>1C</sub>, because of its very high affinity for 5-HT itself. Within the following ten years, the 5-HT<sub>1C</sub>R (later named 5-HT<sub>2C</sub>) was extensively characterized pharmacologically, anatomically and functionally: it was one of the first 5-HT receptors to be sequenced and cloned. The 5-HT<sub>2C</sub>R is a G protein coupled receptor (GPCR), with a very complex gene structure. It constitutes a rarity in the GPCR family: many 5-HT<sub>2C</sub>R variants exist, especially in humans, due to RNA editing, in addition to a few 5-HT<sub>2C</sub>R splice variants. Intense research led to therapeutically active 5-HT<sub>2C</sub> receptor ligands, both antagonists (or inverse agonists) and agonists: keeping in mind that a number of antidepressants and antipsychotics are 5-HT<sub>2C</sub>R antagonists/inverse agonists. Agomelatine, a 5-HT<sub>2C</sub>R antagonist is registered for the treatment of major depression. The agonist Lorcaserin is registered for the treatment of aspects of obesity and has further potential in addiction, especially nicotine/ smoking. There is good evidence that the 5-HT<sub>2C</sub>R is involved in spinal cord injury-induced spasms of the lower limbs, which can be treated with 5-HT<sub>2C</sub>R antagonists/inverse agonists such as cyproheptadine or SB206553. The 5-HT<sub>2C</sub>R may play a role in schizophrenia and epilepsy. Vabicaserin, a 5-HT<sub>2C</sub>R agonist has been in development for the treatment of schizophrenia and obesity, but was stopped. As is common, there is potential for further indications for 5-HT<sub>2C</sub>R ligands, as suggested by a number of preclinical and/or genome wide association studies (GWAS) on depression, suicide, sexual dysfunction, addictions and obesity. The 5-HT<sub>2C</sub>R is clearly affected by a number of established antidepressants/ antipsychotics, and may be one of the culprits in antipsychotic-induced weight gain.

**Keywords:** 5-HT<sub>2C</sub> receptor, GPCR, GWAS, receptor autoradiography, in situ hybridization, species differences, human brain, RNA editing, receptor homomers, heteromers, depression, anxiety, obesity, smoking cessation, spinal cord injury, drug addictions, schizophrenia, suicide, mesulergine, agomelatine, lorcaserin, vabicaserin, sertindole.

## **THE EARLY DAYS: 1983-1988. 5-HT<sub>1C/2C</sub> RECEPTORS CONTRIBUTE TO 5-HT RECEPTOR SUBTYPE AWARENESS:**

The discovery of 5-HT<sub>2C</sub> receptor took place more than 30 years ago, in the middle of a revolutionary period of change in receptor pharmacology (see Lefkowitz, 2004; Palacios et al. 2010). The realization that single entities such as neurotransmitters or hormones were acting through a multiplicity of receptors, which can each take additional forms either by splice or editing variants as is the case for the 5-HT<sub>2C</sub> receptor was “new”, and as discovered later, became even more complex, with the notion of variable constitutive activity and eventually differential coupling or signalling bias. The concept of receptors was initially postulated in the early 1900’s by Paul Ehrlich as “selected binding sites for chemotherapeutic agents” and evolved further as JN Langley formulated the concept of “receptive substances” (see, Bennett 2000).

For much of the 20<sup>th</sup> century, receptors were defined in functional assays based on responses collected in isolated tissues to chemical series and translated in pharmacological effects in animal models and from there extended to the therapeutic use of such new molecular entities. This concept is the basis for the development of still about half of the current therapeutic targets and for the discovery of innumerable drugs.

Despite many decades of receptor pharmacology and related drug discovery, the existence of receptors as actual molecular entities was still debated in the 70’s. The introduction of radioligand binding and affinity labelling which led to the solubilization and purification of receptor proteins, e.g. in the labs of Jean Pierre Changeux and Robert Lefkowitz, (see Lefkowitz 2004) opened the “molecular era of receptor research” and to the cloning of the first receptors: i.e. the cholinergic nicotinic and the  $\beta$  adrenergic receptors which represent the two big families of receptors, i.e. ligand-gated channels and GPCRs. These discoveries led ultimately to Nobel Prizes for the discovery of GPCRs and their structure by Brian Kobilka and Robert Lefkowitz (Chemistry, 2012). Earlier, the Nobel Committee, whether in Physiology/Medicine or Chemistry, recognized the discovery of odorant receptors (Richard Axel and Linda Buck, 2004), the transmitters activating these receptors and playing multiple roles in disease, such as acetylcholine, noradrenaline, dopamine and serotonin or neuropeptides (Sir Bernard Katz, Ulf von Euler and Julius Axelrod, 1970) (Roger Guillemin, Andrew Schally and Rosalyn Yalow, 1977) (Arvid Carlsson, Paul Greengard and Eric Kandel, 2000), the prostaglandins (Sune Bergstrom, Bengt Samuelsson, Sir John Vane, 1982), drugs acting through these receptor (Sir James Black, Gertrude Elion and George Hitchings, 1988), signaling molecules such as cAMP (Earl Sutherland, 1971) and NO/cGMP (Robert Furchgott, Louis Ignarro and Ferid Murad, 1998) or the role of G proteins in GPCRs (Alfred Gilman and Martin Rodbell, 1994).

The development of rapid and simple techniques using radiolabeled ligands (radioligands) to identify receptors in cell-free preparations pioneered by Changeux, Lefkowitz and others, opened new possibilities to study receptors. Radioligand binding was expanded later to intact tissue sections for the localization of receptors in situ at the light microscope level and eventually to whole body imaging in vivo. The combination of these two methods, in addition to second messenger studies and in situ hybridization, constituted the workhorse of much of our work for the next 10 years, until recombinant technologies allowed to investigate cloned receptors. These methodologies revealed many unexpected

features of drug and neurotransmitter receptors. One, which raised tremendous opposition in the beginning, was the multiplicity of receptors for a single neurotransmitter. It was generally considered that the number of receptors for a given neurotransmitter should be limited (to 1 or 2), and some of the resistance to change was nearly dogmatic. From the extreme: “one transmitter-one receptor” to the “liberal”: “one transmitter-two receptors”. Examples: acetylcholine-nicotinic and muscarinic, noradrenaline-alpha and beta adrenergic receptors, histamine-H1 and H2, metabotropic vs ionotropic receptors (e.g. this duality was accepted for acetylcholine, but much less so for 5-HT or GABA receptors). Proposing more than two receptors for a single neurotransmitter was considered non practical by some, heretical by others, and if the proposal was based on radioligand binding, and/or second messengers / electrophysiology, doubly heretical. In other words, radioligand binding was a rather obscure side product of biochemical pharmacology, especially if combined with second messenger studies and/or electrophysiology. Along the same lines, the effects of guanine nucleotides on agonist binding (Laduron 1983), were merely considered as detergent-like effects of GTP and the likes, rather than on active vs. inactive states of the receptor (a few years later in 1994, the Nobel Prize was awarded for the discovery of G-Proteins, see above). However results were accumulating making it difficult to artificially constrain the size of receptor families.

With respect to serotonin, 2 receptors were considered to be optimal in 1983/1984, when we started collaborating on this subject: José María Palacios (JMP), Angel Pazos (AP) and Danny Hoyer (DH). The receptor molecular biology era was only to start a few years later with successful cloning of the beta<sub>2</sub> receptor. There was an interesting twist: by homology screening, the cloning of the beta<sub>2</sub> receptor lead to that of G21 /5-HT<sub>1A</sub> receptor and then to the beta<sub>1</sub> receptor. This was not surprising as 5-HT<sub>1A</sub> receptors have high affinity for beta blockers such as pindolol, as revealed in our binding studies, and of course 5-HT and beta receptors share structural homologies (see Wang et al. 2013; Wacker et al. 2013). Thus in the brain, one would distinguish between 5-HT<sub>1</sub> and 5-HT<sub>2</sub> binding sites (Peroutka and Snyder 1979), labelled by [<sup>3</sup>H]5-HT and [<sup>3</sup>H]spiperone or [<sup>3</sup>H]ketanserin, respectively; keeping in mind that [<sup>3</sup>H]LSD would label both. In the guinea pig ileum, 5-HT-M and 5-HT-D receptors had been known since the mid 1950's (the effects of 5-HT on receptors were first reported in the gastro intestinal tract), but there were no binding studies in the GI tract, primarily since this was the field of physiologists and electro-physiologists (Gaddum and Picarelli 1957; Bradley et al. 1986; Hoyer et al. 1994). It was becoming clear that 5-HT<sub>2</sub> sites and 5-HT-D receptors were very closely related, if not overlapping (Engel et al. 1984). This lead to reconsider the whole nomenclature. In 1984, there was agreement to name these receptors “5-HT<sub>1</sub>-like”, 5-HT<sub>2</sub> (5-HT-D) and 5-HT<sub>3</sub> (5-HT-M). The Bradley scheme was born and the first receptor nomenclature group was in its infancy (Bradley et al. 1986). The 5-HT<sub>4</sub> receptor had already been recognised by Pramod Saxena and colleagues, but it was not an integral part of the new nomenclature, neither were subtypes of 5-HT<sub>1</sub> or 5-HT<sub>2</sub> receptors. There had been at times confusion between 5-HT<sub>3</sub>, 5-HT<sub>4</sub> and 5-HT<sub>M</sub>, receptors, not surprisingly since the tools/ligands used to characterise these receptors were still in their infancy (Hoyer, 1989) and these receptors were primarily investigated in the guinea pig ileum. The ileum is extremely complex, since most known 5-HT receptors are expressed functionally in the gut, although the proportions, localisation and distribution of the various receptors change along the alimentary tract and vary across species.

## **[<sup>3</sup>H]-Mesulergine: A Dopamine D<sub>2</sub> Receptor Ligand That Defines A New 5-HT Binding Site.**

The discovery of the 5-HT<sub>1C</sub> (later 5-HT<sub>2C</sub>) receptor took place at Sandoz (now Novartis) in Basel, Switzerland. Sandoz had a long tradition of working with ergot derivatives with multiple useful pharmacological activities. Semi-synthetic ergot compounds had been developed over the many years in many therapeutic areas, with famous scientists such as Stoll and Hoffman who discovered many ergot alkaloids and eventually LSD in the 1920-1940s (see Giger and Engel 2006). One of the later ergoline-like compounds was CU-32085, also known as mesulergine. It presented interesting dopaminomimetic activities in animal models and was being developed as an anti-parkinsonian drug (Markstein 1983; Enz et al. 1984). Radioligand binding studies with [<sup>3</sup>H]mesulergine were carried out by Dr. Annemarie Closse. Somewhat surprisingly given its dopaminergic profile, [<sup>3</sup>H]mesulergine showed high affinity binding to 5-HT<sub>2</sub> receptors in the rat brain (Closse 1983). It must however be kept in mind that a number of these ergolines like [<sup>3</sup>H]LSD and [<sup>125</sup>I]LSD, have high affinity for both 5-HT<sub>1</sub> and 5-HT<sub>2</sub> receptors, and we will see later that [<sup>125</sup>I]LSD does indeed label 5-HT<sub>2C</sub> receptors. In 1983, having just set up receptor autoradiography developed in Michael Kuhar's laboratory at Johns Hopkins University to label brain tissue sections with radioligands and study brain receptor distribution and pharmacology, JMP decided to investigate the localization and nature of [<sup>3</sup>H]mesulergine binding sites in the brain of various species. Thus, rat brain sections were incubated with [<sup>3</sup>H]mesulergine to generate autoradiograms. When the films were developed, there was disappointment: at first glance the film appeared "empty", as it happens when exposure is short. Similar stories get repeated: when we did the first 5-HT<sub>3</sub> receptor autoradiographic studies with [<sup>3</sup>H]ICS-205930, exposure time reached 5.5 months (!) before we could detect relevant binding in the brain (Waeber et al. 1988). A closer look though, revealed that [<sup>3</sup>H]mesulergine labelled some dark lines which did not correspond to any known neuronal structures or nuclei, namely the choroid plexus. This binding was selectively blocked by co-incubation with low concentrations of "cold" 5-HT. We knew from our own experience that [<sup>3</sup>H]5-HT also labelled intensely the choroid plexus, as well as many other brain areas, but no special attention had been paid to the choroid plexus, as it was not a target for CNS research: for transporters and brain penetration yes, but not for the study of future drug targets in the general field of neurology or psychiatry.

Thus, while one could expect some 5-HT<sub>2</sub> binding as well as dopamine D<sub>2</sub> binding with [<sup>3</sup>H]mesulergine, our first studies were pointing to a very different pattern. Competition studies suggested that we had identified a "new 5-HT-related site". Preliminary autoradiographic data were further confirmed by AP, a postdoctoral fellow who had just joined JMP's team.

These results were first presented at a meeting of the British Pharmacological Society in 1984 in Birmingham and were received with amused comments from established researchers in the field. This coincided with the first nomenclature group to meet and agree on the existence and naming of "5-HT<sub>1-like</sub>", 5-HT<sub>2</sub> and 5-HT<sub>3</sub> receptors; the group convened by Professor Philipp Bradley, precisely in Birmingham (Bradley et al. 1986).

A full description of the pharmacological profile and characteristics of the 5-HT<sub>1C</sub> receptor was published in 1984, and their detailed anatomical distribution, compared to 5-HT<sub>1A</sub> and



5-HT<sub>1B</sub> and 5-HT<sub>2</sub> receptors, was published a year later. Those studies have been cited extensively (Pazos et al. 1984a; Pazos and Palacios 1985; Pazos et al. 1985), as of today 661, 1395 and 899 times respectively.

### **Characterization Of 5-HT<sub>1C</sub> Binding Sites In Pig Choroid Plexus:**

Classical membrane radioligand binding studies are a simple way to study the kinetic features as well as to fully characterize the pharmacological profile of a new binding site with a large number of drugs. In 1983, high throughput screening did not yet exist, and testing 3 Mio compounds in 2.5 days using fluorescent imaging plate readers (FLIPR®) sounded like science fiction. Pipetting was done by hand, the reaction was carried out in 12.5ml tubes incubated in water baths at 37°C, each tube filtered individually, and each filter placed by hand into another large vial which then needed about 10 ml of scintillation fluid, all introduced single handedly into scintillation counters: no 96, 384 or 1536 plates, fed and handled by robots! DH had just joined Sandoz in 1983 following his postdoctoral training in Perry Molinoff's lab (U of Pennsylvania). His PhD thesis dealt with the discovery and development of two highly utilised radioligands for the study of alpha<sub>1</sub> ([<sup>125</sup>I]BE-2254 also known as [<sup>125</sup>I]HEAT) and beta-adrenoceptors ([<sup>125</sup>I]CYP, which will be used later to characterize 5-HT<sub>1B</sub> receptors). Thus, radioligand binding was used massively in the characterization of 5-HT<sub>1C/2C</sub> and other 5-HT receptors in a variety of species. In order to characterize the pharmacological profile of a new binding site, one needs a source of tissue rich in the sites of interest, that can be easily obtained and in sufficient amounts. Since the putative new 5-HT receptor had been initially identified in the choroid plexus, (we later demonstrated its presence in other brain regions), we decided to study its pharmacology by using radioligand binding in choroid plexus membrane preparations. The rat choroid plexus is small and in order to save animal numbers and costs, we turned to the pig plexus. It was indeed cheaper to collect brains from the local slaughterhouse. To obtain a homogeneous choroid plexus membrane preparation was not trivial, since the plexus is primarily a tight mix of vessels and harsh connective tissue. Eventually, we managed to obtain acceptable membrane fractions, allowing to perform regular radioligand binding studies with adequate quality (Pazos et al. 1984a, 1984b; Hoyer et al. 1985a, 1985b). Parallel autoradiographic studies were carried out to define the brain distribution of what was to become the 5-HT<sub>2C</sub> receptor in various species (see below).

Thus, we compared the profiles of [<sup>3</sup>H]mesulergine, [<sup>3</sup>H]5-HT and [<sup>3</sup>H]LSD labelled sites in choroid plexus membranes. The very first studies with [<sup>3</sup>H]mesulergine added an additional surprise. We found that mesulergine had a unique binding profile in the choroid plexus, different from its pharmacology in the rest of the brain. In addition, species differences in the pharmacology of [<sup>3</sup>H]mesulergine binding became evident, a new feature in receptor studies, adding further complexity to the field. A few years later, it was recognized that such differences are real and dictated by the gene structure of these receptors (Hoyer and Middlemiss 1989; Hartig et al. 1996). In essence, human and pig receptors were different from rodent receptors, and we struggled with designing appropriate experiments as well as "selling" the new concept to management, since rodents were/are very commonly used in drug development.

In rat cortex, [<sup>3</sup>H]mesulergine- and [<sup>3</sup>H]ketanserin-labelled sites were indistinguishable (thus classical 5-HT<sub>2</sub> binding); in contrast, porcine and human cortex [<sup>3</sup>H]mesulergine binding sites were pharmacologically distinct from [<sup>3</sup>H]ketanserin-labelled sites, in other words the rank orders of affinity of a great number of compounds although close were clearly different. On the other hand, in the choroid plexus of the three species, [<sup>3</sup>H]mesulergine-, [<sup>3</sup>H]5-HT- and [<sup>3</sup>H]LSD- labelled sites were highly similar, yet different from 5-HT<sub>2</sub> binding e.g. those labelled by [<sup>3</sup>H]ketanserin. [<sup>3</sup>H]mesulergine binding sites in the choroid plexus were named 5-HT<sub>1C</sub>, as our results clearly demonstrated that they were distinct from the 5-HT<sub>1A</sub> and 5-HT<sub>1B</sub> binding sites, the latter two were well characterized as separate entities at that time in our labs. 5-HT<sub>1C</sub> sites had low to very low affinity for a range a “classical” 5-HT<sub>2</sub> ligands such as ketanserin, spiperone, cinanserin or pirenperone, and high affinity for 5-HT. Further, 5-HT<sub>1C</sub> sites were labelled by [<sup>3</sup>H]5-HT, the prototypical 5-HT<sub>1</sub> radioligand. As more receptor families were characterised, it became clear that high affinity [<sup>3</sup>H]5-HT binding was by no means specific for the 5-HT<sub>1</sub> family, but this was one the agreed features of 5-HT<sub>1</sub>-like receptors at the time preceding receptor cloning (Hoyer et al. 1994).

### **5-HT Receptor Autoradiography: The Power Of Anatomical Resolution**

In parallel to the studies carried out in membranes, we performed a detailed autoradiographic characterization of the whole suite of 5-HT binding sites, first in the brain, later in peripheral tissues. We did also compare various species, since we were primarily interested in human pharmacology, yet needed to know about the pharmacology of the commonly used laboratory animals. We were not interested in developing rodent selective drug candidates. Studies were first designed to identify brain areas specially enriched in the different proposed subtypes of 5-HT<sub>1</sub> receptors, in order to reinforce the specificity of 5-HT<sub>1C</sub> sites as a separate entity from the other 5-HT sites/receptors. At that time, 5-HT<sub>1</sub> binding was divided into 5-HT<sub>1A</sub> and 5-HT<sub>1B</sub> (Pedigo et al. 1981). 8-OH-DPAT had just been reported as a 5-HT<sub>1A</sub> selective agonist (Hjorth et al. 1982; Gozlan et al. 1983; Middlemiss and Fozard 1983). [<sup>3</sup>H]8-OH-DPAT was shown to label a more restricted population of sites in the brain than [<sup>3</sup>H]5-HT (Pazos and Palacios 1985; Hoyer et al. 1986b). We used [<sup>3</sup>H]5-HT, [<sup>3</sup>H]-mesulergine, other radioligands and 8-OH-DPAT, SDZ 21-009, (a very useful beta blocker picked by Guenter Engel), and mesulergine itself as the main competing ligands. We identified anatomical areas particularly enriched in each of the 5-HT<sub>1</sub> and 5-HT<sub>2</sub> receptor subtypes: the dentate gyrus of the hippocampus for 5-HT<sub>1A</sub>, the substantia nigra for 5-HT<sub>1B</sub> and, of course, the choroid plexus for the “new” 5-HT<sub>1C</sub> site. These studies contributed to establish a clear separation between 5-HT<sub>1C</sub>, 5-HT<sub>1A</sub> and 5-HT<sub>1B</sub> sites both in terms of pharmacological profile and brain localisation. We also characterized the pharmacological profile of the new receptor at the microscopic level, by constructing autoradiographic competition curves: these studies revealed a pharmacological profile fully comparable to the one found in membranes (see below). They also revealed the first picture of the distribution of this subtype throughout the rat brain: the choroid plexus presented, by far, the highest binding density, but clearly detectable levels of 5-HT<sub>1C</sub> sites were found over the olfactory system, hippocampus (CA1 field), thalamic nuclei, substantia nigra and spinal cord (external); lower levels were detected in neocortex (piriform, cingulate, frontal), putamen, globus pallidus, hypothalamus (ventromedial) and nuclei of the brainstem (i.e., spinal trigeminal nucleus). The autoradiographic studies highlighted the true power of combining the anatomical

dimension to the classical membrane binding strategies: without the initial identification of a region enriched in one class of receptors, it would have been rather unlikely to perform the detailed studies in choroid plexus membranes that eventually led to the full description of the finally re-named 5-HT<sub>2C</sub> receptors. Again, the choroid plexus as opposed to hippocampus or cortex or striatum is not a brain region that would be commonly studied, and in fact is rather difficult to process; almost like performing binding in blood vessel preparations. Later we also used antibodies to localise the new receptor, although one must confess that anti GPCR antibodies have led to a lot of dubious data (Abramowski et al. 1995).

### **Further Characterisation Of 5-HT<sub>1</sub> And 5-HT<sub>2</sub> Sites**

We subsequently showed (Hoyer et al. 1985b) that brain 5-HT<sub>1</sub>/[<sup>3</sup>H]5-HT binding could be displaced in a tri-phasic manner by the beta blocker SDZ 21-009: high affinity for 5-HT<sub>1B</sub> sites, intermediate for 5-HT<sub>1A</sub> and very low affinity for 5-HT<sub>1C</sub> sites. Our autoradiographic data had also demonstrated the ability of this compound to selectively bind to 5-HT<sub>1B</sub> sites in specific brain areas (Hoyer et al. 1985a; 1985b). Some further indole beta blockers turned out to be very important tools for the delineation of 5-HT<sub>1</sub> receptor subtypes. Indeed, we noticed that [<sup>125</sup>I]ICYP ([<sup>125</sup>I]iodocyanopindolol), a very potent antagonist at  $\beta$ -adrenoceptors, which is still the most popular radioligand for labelling these receptors (Engel et al. 1981; Hoyer et al. 1982), was also labelling brain sites sensitive to 5-HT and other serotonergic ligands. Although, the radioligand was initially described as highly specific for beta receptors, we had to admit that it was perfectly suitable to label 5-HT<sub>1B</sub> receptors in rodents. But not in other species, certainly not in pigs or primates, or rabbits; again highlighting species differences.

Using an iterative process, we put bits and pieces together comparing the binding profiles of radioligands known to interact with 5-HT/Dopamine D<sub>1</sub>-D<sub>2</sub>/5-HT<sub>2</sub> or mixed 5-HT<sub>2</sub>/D<sub>2</sub>, beta receptor ligands, and the one that seems to label pretty much everything, [<sup>3</sup>H]LSD and its derivative [<sup>125</sup>I]LSD (Hoyer et al. 1986c). Incidentally, [<sup>125</sup>I]SCH23982 a “selective” dopamine D<sub>1</sub> ligand, and [<sup>125</sup>I]LSD were found to label 5-HT<sub>1C</sub> sites in the choroid plexus (Hoyer and Karpf 1988). We also used [<sup>3</sup>H]8-OH-DPAT which at the time was (and still is) an exquisite tool to define 5-HT<sub>1A</sub> sites, whereas [<sup>3</sup>H]ketanserin turned out to be another valuable tool for labelling 5-HT<sub>2</sub> receptors. Both membrane binding and autoradiographic studies allowed to define the pharmacological profile / rank order of affinities on the new receptor, with the drugs available at that time. In addition to 5-HT and mesulergine, LSD, methysergide and mianserin showed high or very high affinity for 5-HT<sub>1C</sub> receptors; ketanserin, pirenperone and methergine bound to the new site with an intermediate affinity; by contrast, 8-OH-DPAT, (-) SDZ 21-009 and spiperone had low or very low affinity for 5-HT<sub>1C</sub> receptors.

The iterations were multiple: radioligand binding was performed in brain membranes, including choroid plexus, receptor autoradiography in brain slices of various species, and functional models such as contractions of the guinea-pig ileum (Engel et al. 1984; Kalkman et al. 1986), inhibition of 5-HT release in the cerebral cortex (Engel et al. 1986), stimulation or inhibition of cAMP production in hippocampus (Markstein et al. 1986; Schoeffter et al. 1989), in the substantia nigra (Hoyer and Schoeffter 1988; Schoeffter et al. 1988; Schoeffter and Hoyer 1989; Schoeffter et al. 1989), stimulation of PLC



production in choroid plexus (Hoyer et al. 1989) or in smooth muscle cells, contraction or relaxation of various blood vessels (Kalkman et al. 1984; 1986; Doyle et al. 1986; Hoyer 1988a, 1998b; Schoeffter et al. 1989) and in vivo (Kalkman et al. 1984; Doods et al. 1988).

### **5-HT Receptor Binding And Autoradiography In The Human Brain**

After characterizing the properties of the new site in animal brain (mouse, rat, guinea-pig, pig, bovine and many others), we went on with the characterization and localization of 5-HT<sub>1C</sub> receptors in postmortem human brain tissue. Taking advantage of the fact that Dr. Alphonse Probst, a pathologist at the University of Basel, shared a collaboration with the JMP group aimed to visualize and analyse neurotransmitter receptors in human tissue, we applied similar experimental procedures both in membranes and sections from a series of human brains, although confronting the specific limitations associated to the work with postmortem material. By the end of 1985 the anatomical distribution and pharmacological profile of 5-HT<sub>1</sub> and 5-HT<sub>2</sub> receptors in the human brain were obtained, proving to be relatively similar to that reported in animals (choroid plexus starring again). However species differences were highlighted again: the marked differences in 5-HT<sub>1B</sub> pharmacology complicated for quite a while the exact delineation of the distribution of 5-HT<sub>1C</sub> sites in non-choroid plexus areas (Pazos et al. 1987a; 1987b; Hoyer et al. 1986a, 1986b). The high density of 5-HT<sub>1C</sub> receptors in the choroid plexus of all the species investigated was calling for an examination of their potential functional role in the volume and composition of cerebrospinal fluid. We cannulated rat cerebral ventricles and using perfusion with artificial CSF and radiolabeled inulin, examined alterations in the volume of CSF. We found effects of 5-HT and other drugs, but the system was too complex to carry out detailed studies and we did not progress enough to publish. However, Lindvall-Axelsson et al (1998) performed a detailed study in the rabbit, a better suited model, reporting inhibition of CSF production by 5-HT which was blocked by ketanserin.

### **In Situ Hybridization Complements Autoradiography:**

The cloning of 5-HT<sub>1C/2C</sub> receptor (see below) allowed for the visualization of mRNA coding for this receptor by in situ hybridization histochemistry in brain: 5-HT<sub>1C/2C</sub> binding and mRNA distributions were largely overlapping in mammalian brain (Hofman and Mezey 1989; Palacios et al. 1990; Mengod et al. 1990; Pompeiano et al. 1994; Lopez-Gimenez et al. 2001; Serrats et al. 2005; Mengod et al. 2010). There is the occasional mismatch as has been reported for other GPCRs. For instance, high levels of mRNA are found in the habenular nucleus, whereas binding levels are low. The monkey brain was then studied extensively: 5-HT<sub>2C</sub> mRNA is present in choroid plexus, in layer V of most cortical regions, in nucleus accumbens, ventral anterior caudate and putamen, septal nuclei, diagonal band, ventral striatum, and extended amygdala (López-Giménez et al. 2001). Several thalamic, midbrain, and brainstem nuclei also express 5-HT<sub>2C</sub> mRNA. In general, [<sup>3</sup>H]mesulergine binding and mRNA showed a good correlation across the brain, in agreement with a somatodendritic localization of 5-HT<sub>2C</sub> receptors. When there was lack of correlation, this was compatible a possible location on axon terminals, such as in the septal nuclei and horizontal limb of the diagonal band (presence of mRNA with apparent absence of binding sites) and interpeduncular nucleus (presence of binding sites with apparent absence of mRNA). 5-HT<sub>2C</sub> receptors are also present in the spinal cord

(see below). There has been no evidence for 5-HT<sub>2C</sub> binding or mRNA in peripheral tissues.

### **The 5-HT<sub>1C</sub> Receptor Defines A New 5-HT Receptor Family**

It became clear that 5-HT<sub>2</sub> receptors were acting via the PLC/PKC/Calcium pathway, whereas 5-HT<sub>1</sub> receptors were negatively modulating cAMP production (Hoyer 1988a). There was no evidence for cAMP modulation in the choroid plexus (Palacios et al. 1986), whereas stimulation of PLC activity had a 5-HT<sub>1C</sub> profile (Conn and Sanders Bush 1986; Conn et al. 1986; Hoyer et al. 1989). We also suggested that 5-HT<sub>1C</sub> receptors were present in the stomach fundus, and attempted to correlate both activities (5-HT<sub>1C</sub> binding and 5-HT-mediated contraction), with little success. Further, the 5-HT<sub>2B</sub> receptor is expressed in the fundus (Foguet et al. 1992a; 1992b) and there is no evidence that 5-HT<sub>1C</sub> receptors are expressed in the periphery. With the tools available at the time, a pharmacologic differentiation between the two receptors was not easy. Right from the beginning, the pharmacological similarity between 5-HT<sub>1C</sub> and the classical 5-HT<sub>2</sub> receptors in terms of pharmacological profile was rather striking. We thus suggested these receptors to be closely linked (Hoyer 1988a) as confirmed subsequently.

### **POST 1988. THE CLONING OF 5-HT RECEPTORS: 5-HT<sub>1C</sub> BECOMES 5-HT<sub>2C</sub>.**

The 5-HT<sub>1C</sub> receptor, one of the first of the 5-HT family, was cloned before the 5-HT<sub>2</sub> receptor (Lubbert et al. 1987), although the full length 5-HT<sub>1C</sub> sequence came somewhat later. The 5-HT<sub>1C</sub> gene has a rather complex structure (Julius et al. 1988; Saltzman et al. 1991; Yu et al. 1991; Milatovich et al. 1992; Stam et al. 1994). The 5-HT<sub>2</sub> receptor was cloned in close succession (Pritchett et al. 1988; Julius et al. 1989; Foguet et al. 1992a; 1992b). The 5-HT<sub>2</sub> receptor family was then extended, when the fundus receptor was sequenced and cloned, named first 5-HT<sub>2F</sub>, (for fundus), to become 5-HT<sub>2B</sub>. Together, these three receptors showed some marked sequence similarities (Julius et al. 1989; Foguet et al. 1992b) and thus formed a group structurally distinct from the 5-HT<sub>1R</sub> family, which eventually expanded to 5-HT<sub>1B/1D</sub>, 5-HT<sub>1E</sub> and 5-HT<sub>1F</sub> (Hoyer et al. 1994; Hartig et al. 1996).

Logically, the serotonin receptor nomenclature committee agreed that subtypes existed for 5-HT<sub>1</sub> and 5-HT<sub>2</sub> receptors (cloning had strongly supported these views): it was then decided to place the 5-HT<sub>1C</sub> receptor within the 5-HT<sub>2</sub> family. Thus, 5-HT<sub>1C</sub> was re-named 5-HT<sub>2C</sub>, which was the least disruptive move (Humphrey et al. 1993; Hoyer et al. 1994) and the 5-HT<sub>1C</sub> spot remains unassigned.

The availability of recombinant receptors in homogeneous cell population allowed for relatively selective 5-HT<sub>2C</sub> receptor agonists and antagonists to be synthesized, and clinical development followed for conditions such as depression, obesity, addiction, schizophrenia (see Table 1, and Cryan and Lucki 2000; Fletcher et al. 2002a; 2002b; 2004; 2008; 2001; 2012; Kennett et al. 1994; 1996; 2000; Grottick et al. 2000; 2001; 2015; Lee and Meltzer 1994; Niswender et al. 2001; Millan et al. 2003; 2005; 2008; 2011; Millan 2003; 2005; Miller 2005; Higgins et al. 2012; Rauser et al. 2001; Marquis et al. 2007; Cunningham et al. 2011; 2013; Cunningham and Anastasio 2014; Anastasio et al. 2014a, 2014b; 2015).

The progress in the field has been compelling, due to major advances in molecular biology, the availability of selective tools and their judicious use, a lot of 'out of the box' thinking and some neglect for dogmas imposed by self-named experts. Yet, the gene encoding the 5-HT<sub>2C</sub>R is extraordinarily complex and it has taken quite some time to obtain the full sequence (see Lubbert et al. 1987; Julius et al. 1988; Saltzman et al. 1991; Yu et al. 1991; Milatovich et al. 1992; Stam et al. 1994). There are three splice variants of the 5-HT<sub>2C</sub>R: the full length receptor, and two severely truncated forms (Canton et al. 1996; Xie et al. 1996; Liu et al. 1999; Wang et al. 2000; Kishore and Stamm 2006; Kishore et al. 2010; Shen et al. 2013; Bombail et al. 2014), thought to be inactive, although they may serve as chaperones and seem to be affected in disease (Dracheva et al. 2003; 2008a; Flomen et al. 2004; Martin et al. 2013).

### **5-HT<sub>2C</sub> Receptor mRNA Editing.**

Quite exceptionally for a GPCR, the primary transcript of the 5-HT<sub>2C</sub>R is subjected to multiple RNA editing (Burns et al. 1997; Niswender et al. 1999; 2001; Rueter et al. 1999; Fitzgerald et al. 1999; see also Dracheva et al. 2003; 2008a; 2008b; 2009; Camel et al. 2012; Du et al. 2006; 2007; Di Narzo et al. 2014; 2015). So far editing is only known for ionotropic glutamate AMPA receptors. In rodents, there are four editing sites within the coding region of the 5-HT<sub>2C</sub>R, whereas in humans a fifth editing site is present. Together they may produce up to 32 different mRNAs and 24 different proteins. The 5-HT<sub>2C</sub>R is characterized by constitutive activity, the level of which decreases as editing increases (Herrick Davis et al. 1999). For instance, RNA encoding the human 5-HT<sub>2C</sub>R undergoes adenosine-to-inosine RNA editing at five positions, resulting in alterations of amino acids in the second intracellular loop. Edited 5-HT<sub>2C</sub>Rs show reduced G-protein coupling compared to the non-edited isoform, and the fully edited variants (VSV and VGV) show lowest levels of constitutive activity and the unedited form (INI) the highest level. Editing also leads to a loss of the active state of the receptor (Niswender et al. 1999) and a delay in agonist-stimulated calcium release in the fully edited isoforms (Price and Sanders Bush, 2001). The unedited receptor couples to both Gq/11 and G13, whereas editing reduces or eliminates coupling to G13 (Price et al. 2001). Thus, editing may serve to stop constitutive activity by reducing coupling to G proteins. The multiple editing and some splice variants of the 5-HT<sub>2C</sub> receptor are probably not discriminated by antagonist radioligands used in binding/ autoradiographic studies; however, agonist binding such as [<sup>3</sup>H]5-HT, will only label receptors in an active state which depends much on the levels of editing.

### **5-HT<sub>2C</sub> Receptor KO And Knock Down, Transgenic Models:**

5-HT<sub>2C</sub>R-KO or -mutated mice show hyperphagia, late-onset obesity, insulin resistance, and type 2 diabetes (Tecott et al. 1995; Heisler et al. 1998; Nonogaki et al. 1998; Tecott and Abdallah 2003; Wade et al. 2008). Interestingly, fenfluramine has reduced satiating effects in 5-HT<sub>2C</sub>R KO mice (Vickers et al. 1999), suggesting a major role for the 5-HT<sub>2C</sub> receptor in the reduced food intake produced by fenfluramine, norfenfluramine, benfluorex and possible effects on insulin/diabetes of these drugs (Wade et al. 1998). 5-HT<sub>2C</sub>R-KO or -mutated mice also have spontaneous and audio-induced seizures (Brennan et al. 1997; Heisler et al. 1998; 2002) and show locomotor hyperactivity via 5-HT<sub>1B</sub>R (Heisler and Tecott 2000; Rocha et al. 2002). The 5-HT<sub>2C</sub>R knock down produces motor

impulsivity and increased cocaine sensitivity (Anastasio et al., 2015), that may result from an imbalance with the 5-HT<sub>2A</sub> receptor in the medial prefrontal cortex. Further evidence from KO mice and other models suggest a role for the 5-HT<sub>2C</sub> receptors in neuroendocrine responses to stress and an anxiolytic phenotype (Rocha et al. 1993; 1994; Heisler et al. 2007a; 2007b). Interestingly, the effects of 5-HT uptake blockade are reinforced in 5-HT<sub>2C</sub>R KO mice (Cremers et al. 2004). 5-HT<sub>2C</sub>R-selective expression in POMC neurons of 5-HT<sub>2C</sub>R KO mice (Xu et al. 2008; 2010) reverses hyperphagia and restores insulin levels. These studies have been instrumental in directing the preclinical and clinical development of a number of drug candidates, and eventually some clinical translation, although much more work is in progress, especially in the addiction field (see below).

### **5-HT<sub>2C</sub> Receptor Homomers And Heteromers.**

Several members of the 5-HT receptor family, including the 5-HT<sub>2C</sub>R, have been reported to form homodimers (see Herrick-Davis 2013, for a review). 5-HT<sub>2C</sub>R homodimer formation occurs in the endoplasmic reticulum during receptor biosynthesis (Herrick-Davis et al. 2006) and the dimer is then transported through the Golgi complex to the plasma membrane. 5-HT<sub>2C</sub>R homodimers do not form higher order complexes (tetramers or higher) following agonist or inverse agonist treatment (Herrick-Davis et al. 2004; 2007; 2012). The 5-HT<sub>2C</sub>R homodimer interacts with a single G protein, with both active protomers needed for signaling to occur (Herrick-Davis et al. 2005). Homodimerization occurs with both the unedited INI and the fully edited (VSV and VGV) isoforms (Herrick-Davis et al. 2007; 2012). Heterodimers can form between the different editing isoforms of the 5-HT<sub>2C</sub>R. In HEK293 cells, INI/VSV, INI/VGV and VSV/VGV isoform pairs have been reported (Herrick-Davis and Farrington 2011). The native choroid plexus 5-HT<sub>2C</sub>R is expressed as homodimers on the apical surface of the epithelial cells (Herrick-Davis et al. 2015).

Heterodimers between the 5-HT<sub>2C</sub>R and the 5-HT<sub>2A</sub>R are likely to exist, but have not been demonstrated, although 5-HT<sub>2A</sub>R and 5-HT<sub>2C</sub>R protein co-localize in rat medial prefrontal cortex (Anastasio et al., 2015). Furthermore, combination 5-HT<sub>2A</sub> antagonist / 5-HT<sub>2C</sub> agonist seem to act in synergy, which support the claim by Cunningham's group to develop dual compounds for the treatment of various forms of addiction. Thus, subthreshold doses of the 5-HT<sub>2A</sub>R antagonist M100907 combined with the selective 5-HT<sub>2C</sub>R agonist WAY163909 synergistically suppressed cocaine-evoked motor impulsivity, hyperactivity and cocaine-seeking behavior (Cunningham et al. 2013).

The 5-HT<sub>2C</sub>R and ghrelin receptor appear to form heterodimers when overexpressed in HEK293 cells. Further, the two receptors colocalize in cultured primary rat hypothalamic and hippocampal neurons (Schellekens et al., 2015). Interestingly, activation and blockade of 5-HT<sub>2C</sub>R *in vivo* attenuated and potentiated, respectively, the orexigenic effects of ghrelin. It remains to be seen whether compounds such as fenfluramine, norfenfluramine or benfluorex act primarily on these receptor heterodimers or preferentially on 5-HT<sub>2C</sub>R homodimers.

The formation of 5-HT<sub>2C</sub>R and melatonin MT<sub>2</sub>R heterodimers has been reported in transfected cells, and importantly human cortex and hippocampus (Kamal et al., 2015).

The antidepressant / anxiolytic agomelatine displays 5-HT<sub>2C</sub>R antagonist and MT<sub>1</sub> and MT<sub>2</sub> receptor agonist properties. Whether the receptor heterodimer is the target of agomelatine and other antidepressants / anxiolytics remains to be investigated.

The glutamate *N*-Methyl-D-aspartate (NMDA) receptor subunit GluN2A co-localizes with the 5-HT<sub>2C</sub>R in rat spinal cord neurons and synaptosomal fractions (Bigford et al., 2012). 5-HT<sub>2C</sub>R activation enhanced NMDA-evoked motoneuron depolarization (Bigford et al., 2012), suggesting the existence of 5-HT<sub>2C</sub>R / NMDA hetero complex in the spinal cord.

## **THE MODERN ERA: THERAPEUTIC CONSIDERATIONS.**

The clinical relevance of 5-HT<sub>2C</sub>R editing has been linked in genome wide association studies (GWAS), animal models or clinical samples, to suicidality (Niswender et al. 2001), schizophrenia (Sodhi et al. 2001; 2005; Reynolds et al. 2003; 2005; Zhu et al. 2012), anxiety (Hackler et al. 2006; 2007; Heisler et al. 2007b), depression (Iwamoto and Kato 2003; Yang et al. 2004; Iwamoto et al. 2005; 2011), spatial memory (Du et al. 2007), obesity (Yuan et al. 2000; Pooley et al. 2004), antipsychotic-induced weight gain (AIWG) (Basile et al. 2002; Tsai et al. 2002; Templeman et al. 2005; Wallace et al. 2011), addiction or impulsivity (Rocha et al. 2002; Filip and Cunningham 2002; Winstantley et al. 2004; Anastasio et al. 2014a), although it is fair to say that replication failure is frequent and contradictory data are not uncommon in GWAS. 5-HT<sub>2C</sub> receptors have been shown to modulate mesolimbic dopaminergic function, where they exert a tonic inhibitory influence over dopamine neurotransmission (Bubar and Cunningham 2007; Bubar et al. 2011). Therefore, the interest in this receptor as a therapeutic target for treating substance abuse (Bubar and Cunningham 2006; 2008). The 5-HT<sub>2C</sub>R is also believed to mediate the effects of antidepressants, e.g. mirtazapine or agomelatine (Cremers et al. 2004; 2007; see Millan 2003), possibly by stimulating neurogenesis, as well as that of atypical antipsychotics (Berg et al. 1999; Herrick Davis et al. 2000). 5-HT<sub>2C</sub>R are expressed in the amygdala, and fMRI data have demonstrated that 5-HT<sub>2C</sub>R agonists lead to its neuronal activation (Hackler et al. 2007). Other therapeutic indications relate to obesity and possibly epilepsy (Tecott et al. 1995; Brennan et al. 1997; Heisler et al. 1998; 2007a; Tecott and Abdallah 2003) as observed in the first series of receptor transgenic mice and later with 5-HT<sub>2C</sub>R selective ligands (Venzi et al. 2016; Bagdy et al. 2007; Jakus et al. 2003; Isaac 2005). It is still a challenge to synthesise 5-HT<sub>2C</sub>R selective agonists, devoid of significant interactions with the other 5-HT<sub>2</sub> receptor subtypes, since 5-HT<sub>2B</sub> receptor activation results in detrimental cardiac effects such as valvulopathies (see Fitzgerald et al. 2000; Roth 2007), whereas 5-HT<sub>2A</sub>R activation leads to hallucinations (Nichols 2004).

### **Depression And Anxiety: Agomelatine And Others.**

Agomelatine (Valdoxan®, Melitor®, Thymanax®), a selective 5-HT<sub>2C</sub>R antagonist and melatonin<sub>1/2</sub>R agonist, was approved by the EMA and in other countries (but not FDA), for the treatment of major depressive disorders. It has also been considered in the treatment of sleep disorder, generalized anxiety disorders and adjunctive therapy in obsessive compulsive disorders. The recommended dose is 25 mg to be taken at bedtime, the dose may be doubled after 2 weeks if efficacy is lacking. There are some safety issues since liver enzymes are increased in a significant number of patients, although the compound is



generally well tolerated. Thus, the 5-HT<sub>2C</sub>R is involved in the serotonergic regulation of generalized anxiety, depression and possibly bipolar disorders. It has been known for some time that mCPP and MK212 induce anxiogenic-like behaviours in rodents (Kennett et al. 1989; Benjamin et al. 1990; Shepherd et al. 1994; Bilkei-Gorzo et al., 1998; Millan 2003; 2005; Martin et al. 1998; Di Giovanni et al. 2001) and these compounds have been used as tools to induce anxiety and panic in humans (Lowy and Meltzer 1988; Kahn and Wetzler 1991; Sevy et al. 1994; Southwick et al., 1997; Gatch 2003). The anxiogenic effects are likely due to the activation of the 5-HT<sub>2C</sub>R. 5-HT<sub>2C</sub>R knockout mice exhibit an anxiolytic-like phenotype (Heisler and Tecott 2000; Heisler et al. 2007b). Moreover, desensitization of the 5-HT<sub>2C</sub>R in SERT KO mice reduces the anxiety phenotype (Martin et al. 2015) and show antidepressant-like effects (Prisco and Esposito, 1995; Di Giovanni et al. 2006). The situation is however more complex: although, mCPP induces anxiety in mice (Kennett et al. 1989; Nic Dhonnchadha et al. 2003), it has antidepressant-like properties in the anhedonia model in rats (Moreau et al. 1996) and is apparently anorexigenic without inducing anxiety/depression in humans (Thomas et al. 2014). RO60-0175, a 5-HT<sub>2C</sub>R agonist, shows antidepressant and anxiolytic/anti-compulsive like effects in some rodent models (Cryan and Lucki 2000; Nic Dhonnchadha et al. 2003). It seems that anxiogenic-like features of RO60-0175 (Martin et al. 2013; Martin et al. 2014) may be related to its sedative properties (Kennett et al. 2000). Yet, all compounds are not equal: CP809101 is not anxiogenic in some models (Siuciak et al. 2007) but anxiogenic in others (Strong et al. 2009; 2011; Christianson et al. 2010), suggesting that pathway selection may be at play. Thus, some 5-HT<sub>2C</sub>R antagonists have strong anxiolytic/antidepressant properties in numerous tests (Kennett et al., 1994; 1996; 1997; 2000; Wood et al. 2001; Millan, 2005; Harada et al., 2006). On the other hand and surprisingly, both 5-HT<sub>2C</sub>R agonists and antagonists have been reported to have anxiolytic/antidepressant properties, in the chronic mild stress-induced anhedonia and olfactory bulbectomy models of depression. It has been suggested that selective 5-HT<sub>2C</sub>R agonists would be more appropriate to treat depression, obsessive-compulsive disorder or panic attacks, while antagonists would be better suited for generalized anxiety and obsessive-compulsive disorder (Jenck et al. 1998; Millan 2003; 2005). However, the atypical antidepressants mirtazapine and mianserin (Hayasaka et al. 2015) and the recently developed antidepressant agomelatine (Millan et al. 2003; 2011; Millan 2005) have clear antagonistic 5-HT<sub>2C</sub>R profiles. Local activation of the 5-HT<sub>2C</sub>R in the basolateral amygdala is anxiogenic (Campbell and Merchant 2003), whereas 5-HT<sub>2C</sub>R activation in the dorsal periaqueductal grey is anxiolytic (Yamashita et al. 2011). Be it is at it may, agomelatine is a 5-HT<sub>2C</sub>R with additional melatonin 1 and 2 receptor agonism that has been registered for the treatment of major depression in Europe and a number of other countries, but not in the USA. Interestingly, the 5-HT<sub>2C</sub>R receptor may form heterodimers with melatonin receptors (Kamal et al 2015), although the functional consequences for the therapeutic effects of agomelatine need to be clarified. It is clear that other antidepressants display potent 5-HT<sub>2C</sub>R antagonism, e.g. mirtazapine or mianserin, although their receptor profile is by no means selective.

### **Appetite, Satiety And Obesity: Lorcaserin, Fenfluramine And Others.**

There is ample evidence that the 5-HT<sub>2C</sub>R plays a role in the management of hunger, food intake and satiety (Lucki 1998; Blundell 1999; Halford et al. 1997; 1998; Halford and Blundell 2000; Voigt and Fink, 2015). Lorcaserin (Belviq®) is a selective, high-efficacy 5-

HT<sub>2c</sub>R agonist (Thomsen et al. 2008; Smith et al. 2009; 2010) marketed for weight reduction in patients with a body-to-mass (BMI) index of >30 or with a BMI >27 comorbid with type-2 diabetes, hypertension or dyslipidemia (FDA (2012): <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm309993.htm>). The development of Lorcaserin was based on the knowledge accumulated with previously developed selective ligands such as the agonists RO60-0175 (Fletcher et al. 2004), WAY163909 (Dunlop et al. 2005; 2006) or the antagonist SB242084 (Bromidge et al. 1997) and SB206553 (Kennett et al. 1996), but also from older compounds such as fenfluramine, dexfenfluramine, mCPP or MK212, which act as 5-HT<sub>2c</sub>R agonists and various antipsychotics or cyproheptadine which act as 5-HT<sub>2c</sub>R antagonists. The 5-HT releaser d-fenfluramine and its active metabolite d-norfenfluramine, other preferential 5-HT<sub>2c</sub>R agonists such as mCPP or MK212, evoke hypophagia and increase satiety in rodents, keeping in mind that mCPP has anxiogenic effects. The effects on food intake are blocked by 5-HT<sub>2c</sub>R antagonists or by the constitutive 5-HT<sub>2c</sub>R KO (Kennett and Curzon 1988; Tecott et al. 1995; Halford et al. 1997; Vickers et al. 1999; Dalton et al. 2006; Nonogaki et al. 1998; 2008). Selective 5-HT<sub>2c</sub>R agonists such as lorcaserin, RO60-0175 or WAY163909 do consistently suppress food intake (Clifton et al. 2000; Hewitt et al. 2002; Somerville et al., 2007; Thomsen et al., 2008; Grottick et al. 2000; 2015; Higgs et al. 2016). Interestingly, WAY163909 decreased food intake in normal Sprague–Dawley rats, obese Zucker rats and diet-induced obese mice without the anxiogenic effects of mCPP (Dunlop et al. 2005; 2006). Constitutive 5-HT<sub>2c</sub>R knockout mice show hypophagia and increased body mass in the context of both insulin resistance and late-onset obesity (Tecott et al. 1995; Nonogaki et al. 2008). Some 5-HT<sub>2c</sub>R antagonists such as cyproheptadine disrupt the satiety sequence and increase appetite (Chinuck et al. 2007; Bergen 1964; Ishii et al. 2003). Weight gain and a greater relative risk of metabolic dysfunction and diabetes is associated with atypical antipsychotics with 5-HT<sub>2c</sub>R antagonist properties, such as clozapine and olanzapine in both patients and animals (Wirshing et al. 1999; DeLuca et al. 2007; Kirk et al. 2009). Thus 5-HT<sub>2c</sub>R antagonism may lead to highly detrimental side effects and explains in part the lack of compliance seen with some atypical antipsychotics. However, the situation may be somewhat more complex, since selective 5-HT<sub>2c</sub>R antagonists may increase (Bonhaus et al. 1997; Higgs et al. 2016;) or decrease food intake depending upon the rodent preclinical model (Kennett et al. 1997; Murotani et al. 2011; Higgs et al. 2016). What is clear however, is that 5-HT<sub>2c</sub>R agonism has positive effects in preclinical models of food intake and satiety, and that such effects may also translate positively with respect to diabetes; keeping in mind that all 5-HT<sub>2c</sub>R are not equal, more specifically with respect to biased signalling. Thus, d-fenfluramine and RO60-0175 reduce the rate of feeding and meal size and increase the latency to feed (Clifton et al., 2000). The effects of d-fenfluramine are markedly reduced in 5-HT<sub>2c</sub>R KO mice (Vickers et al. 1999). Lorcaserin reduces the number of licking bouts probably by promoting satiety (Higgs et al. 2016; Davis et al. 2001). The sites of action of lorcaserin and other selective 5-HT<sub>2c</sub>R ligands in the mechanisms underlying satiety are to be found in hypothalamic and midbrain/hindbrain circuits that modulate energy balance and glucose homeostasis in concert with the periphery (Gautron et al. 2015; Voigt and Fink 2015). Multiple hypothalamic nuclei express 5-HT<sub>2c</sub>R (van de Kar and Lorens 1979; Peyron et al. 1998; Hoffman and Mezey 1989; Molineaux et al. 1989; Mengod et al. 1990; Pompeiano et al. 1994). Indeed, arcuate nucleus POMC neurons expressing 5-HT<sub>2c</sub>R are activated by d-fenfluramine and mCPP (Heisler et al. 2002; Lam et al. 2008; Xu et al. 2008; 2010), which translates into

the synthesis of  $\alpha$ -MSH.  $\alpha$ -MSH in turn, acts on melanocortin 4 receptors in the hypothalamic paraventricular nucleus to promote satiety, weight loss and glucose regulation (Heisler et al. 2007a; Zhou et al. 2007; Xu et al. 2008; 2010; Berglund et al. 2013). Mice with a selective 5-HT<sub>2C</sub>R KO in POMC neurons, have normal body weight, and are insensitive to d-fenfluramine- or mCPP-evoked hypophagia; these mice develop a metabolic syndrome, with hyperinsulinemia, hyperglucagonemia, hyperglycemia, and insulin resistance (Berglund et al. 2013). This syndrome can be reversed by re-expressing the 5-HT<sub>2C</sub>R in POMC neurons (Xu et al. 2008). Interestingly, female mice appear to be different in that respect, leading to speculation about possible sex differences in the prevalence of obesity (Burke et al. 2016). Another interesting interplay has been reported between the 5-HT<sub>2C</sub>R and the leptin system. Co-administration of mCPP and leptin results in an additive reduction in body weight in diet-induced obese mice (Yan et al. 2015). 5-HT<sub>2C</sub>R KO mice show leptin-independent hyperphagia and a diabetic phenotype (Nonogaki et al. 1998; 2008), whereas double leptin and 5-HT<sub>2C</sub>R KO mice show a synergistic disruption of glucose homeostasis and a profound diabetes phenotype (Wade et al. 2008). Transgenic overexpressing leptin and 5-HT<sub>2C</sub>R KO mice have a lean phenotype on a chow diet; by contrast, on a high fat diet, these mice become markedly obese (Wang and Chehab 2006). Stimulation of the 5-HT<sub>2C</sub>R activates the same POMC neurons activated by leptin (Qiu et al. 2007; 2010). Thus, the 5-HT and leptin systems may function independently, but within POMC neurons of the hypothalamus, they may control satiety and energy reserves in a coordinated fashion (Halford and Blundell 2000).

### **Schizophrenia: Vabicaserin, Sertindole And The Others.**

Both selective 5-HT<sub>2C</sub>R agonists and antagonists have been suggested for the treatment of schizophrenia, however so far, the clinical outcome has been disappointing. 5-HT<sub>2C</sub>R antagonism may be effective in suppressing positive symptoms, while 5-HT<sub>2C</sub>R agonism may be correcting the negative symptoms and cognitive impairments (Wood et al. 2001; Rosenzweig-Lipson et al. 2007a; 2007b; 2012) with placebo like motor side effects (Di Giovanni et al. 2006; Di Giovanni and De Deurwaerdere 2016). The features of some atypical antipsychotics led to 5-HT<sub>2C</sub>R blockade as a strategy to improve the efficacy of dopamine antagonists in long-term treatments (Meltzer, 1999). On the other hand, one of the great expectations was that 5-HT<sub>2C</sub>R agonists would have antipsychotic effects without inducing AIWG and altering glucose homeostasis, a negative feature of a number of atypical antipsychotics. Further, experimental evidence suggested that 5-HT<sub>2C</sub>R agonism might increase the efficacy of typical and atypical antipsychotics, allowing dose-sparing with a reduction of motor side-effects (Grauer et al. 2009). However, Vabicaserin a potential antipsychotic and anorectic with high agonist efficacy at the 5-HT<sub>2C</sub>R (Dunlop et al. 2011), although improving positive symptoms (Shen et al., 2014), did not meet the primary efficacy endpoints (see ClinicalTrials, 2014: <https://clinicaltrials.gov/ct2/show/results/NCT00563706?term=vabicaserin&rank=2>). Its clinical development by Pfizer was terminated. On the other hand, Sertindole, (Juruena et al. 2011) a potent 5-HT<sub>2C</sub>R inverse agonist, and dopamine D<sub>2</sub>,  $\alpha_1$ -adrenergic receptor and 5-HT<sub>2A</sub>R antagonist (Herrick-Davis et al. 2000; Hietala et al. 2001), was either not registered (USA) or withdrawn from the market (Europe), due to cardiovascular side effects. Sertindole was effective in reducing anxiety, improving cognition/memory and brain plasticity, most probably by reducing 5-HT<sub>2C</sub>R tonic activation (Hietala et al., 2001).

In other words, clinical data have not conclusively proven or disproven the therapeutic potential of 5-HT<sub>2C</sub>R modulating ligands in schizophrenia, thus the jury is still out.

### **RNA Editing, Spinal Cord Injury And More: A Case For Inverse 5-HT<sub>2C</sub> Receptor Agonists**

Spinal cord injury (SCI) patients suffer from paralysis of muscles innervated by motor neurons below the injury site. Weeks to months following injury, some restoration of motor neuron excitability may take place which may be associated with some recovery of motor function. However, that recovery is often accompanied by marked muscle spasms that may be spontaneous or can be triggered by various stimuli. A number of SCI studies (Murray et al. 2010) suggest a role for constitutive activation of the 5-HT<sub>2C</sub>R (and possibly 5-HT<sub>2B</sub>R) in this process in both SCI patients and rodents (rats and mice) subjected to SCI (Fouad et al. 2010; Murray et al. 2011; Husch et al. 2012). In rats, following chronic SCI, electrical stimulation of the tail results in sustained muscle spasms; administration of a neutral 5-HT<sub>2C</sub>R antagonist does not affect these spasms, whereas the 5-HT<sub>2C</sub>R inverse agonists SB206553 and cyproheptadine inhibit the spasms most probably by blocking constitutively active 5-HT<sub>2C</sub>R. These effects can be reproduced in the isolated spinal cord in vitro, ruling out a role for local 5-HT in the spasms. Along these lines, chronic SCI was associated with a fourfold increase in expression of the unedited, constitutively active isoform of the 5-HT<sub>2C</sub>R. In SCI patients, leg muscle spasms evoked by cutaneous stimulation to the foot are significantly reduced by oral administration of cyproheptadine. These data suggest the use of 5-HT<sub>2C</sub>R inverse agonists (and possibly 5-HT<sub>2B</sub>R antagonist) to manage SCI spasticity. However, recovery of locomotion in rats following partial SCI was also inhibited by SB206553, implying that constitutive 5-HT<sub>2C</sub>R activity is needed for normal locomotion. Thus a therapeutic window is to be considered when using such agents.

5-HT<sub>2C</sub>R RNA editing is not limited to SCI, a number of attempts have been made to relate editing to psychiatric disorders and suicide (e.g. Niswender et al. 2011; Gurevich et al. 2002; Lyddon et al. 2013). It is clear that in some brain regions and depending on state, native 5-HT<sub>2C</sub>R display constitutive activity which can vary largely (Di Giovanni et al. 1999; Di Matteo et al. 2000; Gobert et al. 2000; Leggio et al. 2009; Navailles et al. 2004; 2013a; 2013b). A number of antipsychotics behave actually as inverse agonists (Berg et al. 1999; Herrick-Davis et al. 2000; Rauser et al. 2001; Navailles et al., 2004; Aloyo et al. 2009; Sullivan et al; 2015) and if the 5-HT<sub>2C</sub>R is a target, their effectiveness may depend on the level of constitutive activity of the receptor (Navailles et al. 2013b). A complicating factor is that constitutive activity may vary with transduction pathway (Berg et al. 1994; 1998a; 1998b; 2001; 2008a; 2008b; Moya et al. 2007; Wang et al. 2000; Werry et al. 2005; 2008; Berg and Clarke 2009), receptor desensitization and trafficking may be at play as well (Berg et al. 1999; Marion et al., 2004) and different ligands may possess different pathway selectivity. In other words, the situation may be even more complex than ever envisaged and again the status of the receptor may well be disease- and cell-type dependent.

### **Addiction And Substance Use Disorders: Lorcaserin.**



The role of the 5-HT<sub>2C</sub>R in various addictive processes has been amply investigated. 5-HT<sub>2C</sub>R agonists suppress nicotine intake and nicotine-seeking in preclinical models (Grottick et al. 2001; Levin et al. 2011; Fletcher et al. 2012; Higgins et al. 2012) leading to clinical trials with lorcaserin in nicotine abuse (Eisai, 2014: <http://www.eisai.com/news/news201465.html>). The early clinical data suggest lorcaserin given 10 mg twice daily, to increase abstinence from nicotine modestly but significantly, as may be expected from preclinical studies dealing with other substance abuse paradigms such as cocaine and other psychostimulants, ethanol and opiates as well as factors involved in relapse, impulsivity and cue reactivity (Cunningham et al. 2011; 2013; Cunningham and Anastasio, 2014; Rezvani et al., 2014; Howell and Cunningham 2015; Harvey-Lewis et al. 2016). Cocaine administration elevates 5-HT in the Nucleus Accumbens (NAc) (Parsons and Justice 1993; Parsons et al. 1995; Howes et al. 2000). 5-HT<sub>2C</sub>R KO mice show an increased motivation to self-administer cocaine and cocaine-induced elevation in dopamine in the NAc (Rocha et al. 2002). A 5-HT<sub>2C</sub>R agonist, enhances, whereas a 5-HT<sub>2C</sub>R antagonist inhibits, the elevated dopamine efflux in the NAc evoked by cocaine administration (Navailles et al. 2004; 2008; Cathala et al. 2015). Selective 5-HT<sub>2C</sub>R agonists e.g. RO60-0175 or WAY163909 suppress voluntary intake of cocaine (Grottick et al. 2000; Fletcher et al. 2002a; 2004; Neisewander and Acosta 2007; Cunningham et al., 2011) probably via NAc dopamine increases. 5-HT<sub>2C</sub>R stimulation dose-dependently suppresses cocaine-evoked or exposure to cocaine-associated cues (Grottick et al. 2000; Neisewander and Acosta 2007; Burbassi and Cervo 2008; Fletcher et al. 2002a; 2004; 2008; 2011; Cunningham et al. 2011; Swinford-Jackson et al. 2016). Selective 5-HT<sub>2C</sub>R blockade produces opposite effects on self-administration of low doses of cocaine (Fletcher et al. 2002a) and enhances cocaine-evoked reinstatement of drug-seeking in rodents (Fletcher et al. 2002a; Pelloux et al. 2012). In non-human primates, 5-HT<sub>2C</sub>R agonism attenuated the stimulant, reinforcing and reinstatement effects of cocaine, which are blocked by the 5-HT<sub>2C</sub>R antagonist SB242084 (Manvich et al. 2012a; 2012b; Ruedi-Bettschen et al. 2015). SB242084 itself may induce modest stimulant effects in primates (Manvich et al. 2012a; 2012b), although this data is open for discussion (Ruedi-Bettschen et al., 2015). The 5-HT<sub>2C</sub>R mediated inhibitory tone on cocaine reward and cue reactivity may originate in the medial prefrontal cortex (mPFC) as suggested by local administration studies (Cunningham and Anastasio 2014; Howell and Cunningham 2015; Di Giovanni and De Deurwaerdere 2016). The 5-HT<sub>2C</sub>R functional status in the orbitofrontal cortex may also be a contributor to the vulnerability of impulsive rats to cocaine reward and cue reactivity (Besson et al. 2013). Altogether, the data suggest that the functional status of the cortical 5-HT<sub>2C</sub>R system may be a mechanistic driver in the generation of cocaine use disorder and relapse phenomena, and abstinent cocaine users exhibit lower sensitivity to the effects of 5-HT<sub>2C</sub>R agonists (Lee and Meltzer 1994; Buydens-Branchey et al. 1997; Patkar et al. 2006; Liu et al. 2011; 2012; Anastasio et al. 2014a). Stimulation of the 5-HT<sub>2C</sub>R is also suppressing ethanol self-administration (Maurel et al. 1999; Tomkins et al. 2002; Kasper et al. 2013; Rezvani et al. 2014) and reinstatement in rodents (Kasper et al. 2013). Further, ethanol vapor exposure leads to an increased corticostriatal and hypothalamic 5-HT<sub>2C</sub>R mRNA, increased 5-HT<sub>2C</sub>R protein in the NAc and 5-HT<sub>2C</sub>R pre-mRNA editing (Yoshimoto et al. 2012; Watanabe et al. 2014). The behavioral effects of d-amphetamine (O'Neill et al. 1999; Rippberger et al. 2015; Wohr et al. 2015), 3,4-methylenedioxymethamphetamine (MDMA) (Bankson and Cunningham 2002; Fletcher et al. 2002b), methamphetamine (Steed et al. 2011; Graves and Napier 2012), and the marijuana alkaloid  $\Delta^9$ -THC (Ji et al. 2006) can be modulated



by the administration of 5-HT<sub>2C</sub>R agonists, thus extending the potential therapeutic value of selective 5-HT<sub>2C</sub>R agonists in the treatment of substance abuse. Systemic administration of dexfenfluramine blocks heroin self-administration in rats (Wang et al. 1995). Selective 5-HT<sub>2C</sub>R activation reduces opioid-induced behavioral sensitization (Wu et al. 2015; Zhang et al. 2016). Finally, pre-clinical data presented at the ISSR 2016 meeting in Seattle by Kathy Cunningham's group suggest that lorcaserin may be effective in alleviating oxycodone addiction in human subjects.

## CONCLUSION

The discovery of the 5-HT<sub>2C</sub>R resulted from a good mix of experimental design and serendipity and excellent collaborative spirit: having at hand a number of (radio)ligands was essential as was the use of autoradiography that pointed to the choroid plexus. This is not a tissue neuroscientist in big Pharma used to work with, unless one has a dedicated interest in blood brain barrier. Thus seeing the high receptor expression in the brain attracted our attention and allowed the characterization of a binding site that was clearly different from what had been described previously. The pharmacological characterization of the then called 5-HT<sub>1C</sub> receptor, led us to rethink the nomenclature of 5-HT receptors, starting with the 5-HT<sub>1</sub> receptor subfamily. This was a rather controversial subject, since some experts at the time barely recognized the existence of 5-HT<sub>1</sub> receptors: Bradley and colleagues limited that family to the general but rather vague concept of "5-HT<sub>1</sub>-like". We had already made up our mind that subtypes of 5-HT<sub>1</sub> receptors existed, 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, rapidly expanding to 5-HT<sub>1D</sub>, although the latter two were largely species variants as suggested in binding, 2<sup>nd</sup> messengers and functional studies across species (Hoyer and Middlemiss 1989), as confirmed by cloning (Hartig et al. 1996; Hoyer et al. 2002). For a short while we thought that the functional correlate to the 5-HT<sub>1C/2C</sub> site was the receptor described by John Vane in the stomach fundus, but although similar, it became evident following its cloning that 2C and 2B were indeed different! Many years later, (drug development can be a very long enterprise), it becomes clear that the original 5-HT<sub>1C</sub> site did make relevant contributions to modern pharmacology, not only to nomenclature. The development of selective 5-HT<sub>2C</sub>R selective drugs has pioneered the demonstration of the capability of certain ligands to differentially activate different signal transduction pathways (Berg et al. 1998a; 1998b; 2003): this evidence has been instrumental for the concept of "ligand-dependent functional selectivity". In addition to challenging the dogma of classical pharmacology, this concept has a clear impact on drug discovery (Millan et al. 2003). The 5-HT<sub>2C</sub>R is undoubtedly one of the most complex members of the GPCR superfamily, given its multiple editing and splice variants, yet it is clearly the target of a number of drugs which may act rather differently in health and disease. The clinical development of agomelatine as an antidepressant as a potent 5-HT<sub>2C</sub>R antagonist and melatonin receptor agonist aimed at improving sleep, is a first illustration of what selective modulation of 5-HT<sub>2C</sub>R can achieve clinically. With the marketing of the high-efficacy 5-HT<sub>2C</sub>R agonist lorcaserin (Belviq<sup>®</sup>) for obesity (and possibly smoking) and the active investigation of its potential therapeutic value for addictive disorders and epilepsy, for example, the field is gaining valuable information concerning the clinical opportunities for 5-HT<sub>2C</sub>R agonists. Some of the unwanted effects on body mass of both older and newer antipsychotics may be explained by their 5-HT<sub>2C</sub>R antagonism and this knowledge should help to design better antipsychotics devoid of massive weight gain and metabolic syndrome, which limits compliance for otherwise reasonably good medications. However, the situation is

probably more complex since not all 5-HT<sub>2C</sub>R antagonists induce weight gain (e.g. agomelatine). The 5-HT<sub>2C</sub>R may well be one of the two primary targets of fenfluramine/dexfenfluramine/benfluorex and explain their effects of weight loss, due to 5-HT<sub>2C</sub>R agonism. Obviously, their 5-HT<sub>2B</sub>R agonism represented a major and dramatic “side” effect and led to their discontinuation and that of other 5-HT<sub>2B</sub>R agonists (Roth 2007). Surprisingly, it would seem that 5-HT<sub>2C</sub>R agonism (Vabicaserin), may also be an approach to treat different aspects of schizophrenia, although more robust clinical data are needed before drawing firm conclusions. Also surprising, is the fact that both 5-HT<sub>2C</sub>R agonists and antagonists have been reported to have antidepressant activities in animal models; is this related to pathway selection, inverse agonism or disease model? The complexity of the 5-HT<sub>2C</sub>R is even greater than just expected from RNA editing and splicing: 5-HT<sub>2C</sub>R are able to form homodimers that seem necessary for signal transduction and heteromers with e.g. NMDA or melatonin or ghrelin receptors (Herrick-Davis 2013; Herrick-Davis et al. 2004; 2005; 2006; 2007; 2012; 2015; Herrick-Davis and Farrington 2011; Bigford et al. 2012; Kamal et al. 2015; Schellekens et al. 2015). The latter raise further questions about the actual target of drugs such as agomelatine or lorcaserin and their effects in depression or eating behaviour. 5-HT<sub>2C</sub>R as many others have a complex pattern of interactions with multiple GIPs (GPCR interacting proteins, see e.g. Becamel et al. 2001; 2002; 2004; Parker et al. 2003; Gavarini et al. 2006; Labasque et al. 2008; Maillet et al. 2008; Kleene et al. 2015). Finally, 5-HT<sub>2C</sub>R antagonists (or at least inverse agonists), may help in controlling involuntary movements / muscle spasms that result from a marked increase in constitutive 5-HT<sub>2C</sub>R activity in spinal cord injury patients. Future studies are still required to further untangle the complexities of 5-HT<sub>2C</sub>R signalling, RNA editing and the neuronal mediators which regulate behaviour and physiology through this fascinating receptor that was first seen in the choroid plexus: “2C is to believe”.

## REFERENCES

- Abramowski D, Rigo M, Duc D, Hoyer D, Staufenbiel M (1995) Localization of the 5-hydroxytryptamine<sub>2C</sub> receptor protein in human and rat brain using specific antisera. *Neuropharmacology* **34**:1635-1645.
- Aloyo VJ, Berg KA, Spampinato U, Clarke WP, Harvey JA (2009) Current status of inverse agonism at serotonin(2A) (5-HT(2A)) and 5-HT(2C) receptors. *Pharmacol Ther* **121**:160-173.
- Anastasio NC, Liu S, Maili L, Swinford SE, Lane SD, Fox RG, Hamon SC, Nielsen DA, Cunningham KA, Moeller FG (2014a) Variation within the serotonin (5-HT) 5-HT<sub>2C</sub> receptor system aligns with vulnerability to cocaine cue reactivity. *Transl Psychiatry* **4**:e369.
- Anastasio NC, Stutz SJ, Fox RG, Sears RM, Emeson RB, DiLeone RJ, O'Neil RT, Fink LH, Li D, Green TA, Moeller FG, Cunningham KA (2014b) Functional status of the serotonin 5-HT<sub>2C</sub> receptor (5-HT<sub>2C</sub>R) drives interlocked phenotypes that precipitate relapse-like behaviors in cocaine dependence. *Neuropsychopharmacology* **39**:370-382.
- Anastasio NC, Stutz SJ, Fink LH, Swinford-Jackson SE, Sears RM, DiLeone RJ, Rice KC, Moeller FG, Cunningham KA (2015) Serotonin (5-HT) 5-HT<sub>2A</sub> receptor (5-HT<sub>2A</sub>R): 5-

HT<sub>2C</sub>R imbalance in medial prefrontal cortex associates with motor impulsivity. *ACS Chem Neurosci* **6**:1248-1258.

Bagdy G, Kecskemeti V, Riba P, Jakus R (2007) Serotonin and epilepsy. *J Neurochem* **100**:857-873.

Bankson MG, Cunningham KA (2002) Pharmacological studies of the acute effects of (+)-3,4- methylenedioxymethamphetamine on locomotor activity: role of 5- HT(1B/1D) and 5-HT(2) receptors. *Neuropsychopharmacology* **26**:40-52.

Basile VS, Masellis M, De Luca V, Meltzer HY, Kennedy JL (2002) 759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. *Lancet* **360**:1790-1791.

Becamel C, Figge A, Poliak S, Dumuis A, Peles E, Bockaert J, Lubbert H, Ullmer C (2001) Interaction of serotonin 5-hydroxytryptamine type 2C receptors with PDZ10 of the multi-PDZ domain protein MUPP1. *The Journal of biological chemistry* **276**:12974-12982.

Becamel C, Alonso G, Galeotti N, Demey E, Jouin P, Ullmer C, Dumuis A, Bockaert J, Marin P (2002) Synaptic multiprotein complexes associated with 5-HT(2C) receptors: a proteomic approach. *EMBO J* **21**:2332-2342.

Becamel C, Gavarini S, Chanrion B, Alonso G, Galeotti N, Dumuis A, Bockaert J, Marin P (2004) The serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors interact with specific sets of PDZ proteins. *J Biol Chem* **279**:20257-20266.

Benjamin D, Lal H, Meyerson LR (1990) The effects of 5-HT<sub>1B</sub> characterising agents in the mouse elevated plus-maze. *Life Sci* **47**:195-203.

Bennett MR, (2000) The concept of transmitter receptors: 100 years on. *Neuropharmacology* **39**: 523-546.

Berg KA, Clarke WP, Sailstad C, Saltzman A, Maayani S (1994) Signal transduction differences between 5-hydroxytryptamine type 2A and type 2C receptor systems. *Mol Pharmacol* **46**:477-484.

Berg KA, Maayani S, Goldfarb J, Clarke WP (1998a) Pleiotropic behavior of 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptor agonists. *Ann NY Acad Sci* **861**:104-110.

Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP (1998b) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. *Mol Pharmacol* **54**:94-104.

Berg KA, Stout BD, Cropper JD, Maayani S, Clarke WP (1999) Novel actions of inverse agonists on 5-HT<sub>2C</sub> receptor systems. *Mol Pharmacol*. **55**:863-72

Berg KA, Cropper JD, Niswender CM, Sanders-Bush E, Emeson RB, Clarke WP (2001) RNA-editing of the 5-HT(2C) receptor alters agonist-receptor-effector coupling specificity. *Br J Pharmacol* **134**:386-392.

Berg KA, Cropper JD, King BD, Clarke WP, (2003) Effector pathway- dependence of

ligand-independent 5-HT<sub>2C</sub> receptor activity. *FASEB J* 17: A1021.

Berg KA, Clarke WP, Cunningham KA, Spampinato U (2008a) Fine-tuning serotonin<sub>2c</sub> receptor function in the brain: molecular and functional implications. *Neuropharmacology* **55**:969-976.

Berg KA, Dunlop J, Sanchez T, Silva M, Clarke WP (2008b) A conservative, single-amino acid substitution in the second cytoplasmic domain of the human Serotonin<sub>2C</sub> receptor alters both ligand-dependent and -independent receptor signaling. *J Pharmacol Exp Ther* **324**:1084-1092.

Berg KA, Clarke WP (2009) Functional Selectivity at Serotonin Receptors, in *Functional Selectivity of G Protein-Coupled Receptor Ligands* (Neve KA ed) pp 155-176, Humana Press.

Bergen SS, Jr. (1964) Appetite Stimulating Properties of Cyproheptadine. *Am J Dis Child* **108**:270-273.

Berglund ED, Liu C, Sohn JW, Liu T, Kim MH, Lee CE, Vianna CR, Williams KW, Xu Y, Elmquist JK (2013) Serotonin 2C receptors in pro-opiomelanocortin neurons regulate energy and glucose homeostasis. *J Clinical Investigation* **123**:5061-5070.

Besson M, Pelloux Y, Dilleen R, Theobald DE, Lyon A, Belin-Rauscent A, Robbins TW, Dalley JW, Everitt BJ, Belin D (2013) Cocaine modulation of frontostriatal expression of Zif268, D<sub>2</sub>, and 5-HT<sub>2c</sub> receptors in high and low impulsive rats. *Neuropsychopharmacology* **38**:1963-1973.

Bigford GE, Chaudhry NS, Keane RW, Holohean AM (2012) 5-Hydroxytryptamine 5HT<sub>2C</sub> receptors form a protein complex with N-methyl-D-aspartate GluN2A subunits and activate phosphorylation of Src protein to modulate motoneuronal depolarization. *J Biol Chem* **287**:11049-11059.

Bilkei-Gorzo A, Gyertyan I, Levay G (1998) mCPP-induced anxiety in the light-dark box in rats--a new method for screening anxiolytic activity. *Psychopharmacology (Berl)* **136**:291-298.

Blundell JE (1999) The control of appetite: basic concepts and practical implications. *Schweiz Med Wochenschr* **129**:182-188.

Bombail V, Qing W, Chapman KE, Holmes MC (2014) Prevention of 5-hydroxytryptamine<sub>2C</sub> receptor RNA editing and alternate splicing in C57BL/6 mice activates the hypothalamic-pituitary-adrenal axis and alters mood. *Eur J Neurosci* **40**:3663-3673.

Bonhaus DW, Weinhardt KK, Taylor M, DeSouza A, Mcneeley PM, Szczepanski K, Fontana DJ, Trinh J, Rocha CL, Dawson MW, Flippin LA, Eglen RM (1997) RS-102221: A novel high affinity and selective, 5-HT<sub>2c</sub> receptor antagonist. *Neuropharmacology* **36**:621-629.

Bradley PB, Engel G, Feniuk W, Fozard JR, Humphrey PPA, Middlemiss DN,

Mylecharane EJ, Richardson BP, Saxena PR (1986) Proposals for the classification and nomenclature of functional receptors for 5- hydroxytryptamine. *Neuropharmacol.* 25: 563-576.

Brennan TJ, Seeley WW, Kilgard M, Schreiner CE, Tecott LH (1997) Sound-induced seizures in serotonin 5-HT<sub>2C</sub> receptor mutant mice. *Nature Genet* **16**:387-390.

Bromidge SM, Duckworth M, Forbes IT, Ham P, King FD, Thewlis KM, Blaney FE, Naylor CB, Blackburn TP, Kennett GA, Wood MD, Clarke SE (1997) 6-Chloro-5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbonyl]- indoline (SB-242084): the first selective and brain penetrant 5-HT<sub>2C</sub> receptor antagonist. *J Med Chem* **40**:3494-3496.

Bubar MJ, Cunningham KA (2006) Serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors as potential targets for modulation of psychostimulant use and dependence. *Curr Top Med Chem* **6**:1971-1985.

Bubar MJ, Cunningham KA (2007) Distribution of serotonin 5-HT<sub>2C</sub> receptors in the ventral tegmental area. *Neuroscience* **146**:286-297.

Bubar MJ, Cunningham KA (2008) Prospects for serotonin 5-HT<sub>2R</sub> pharmacotherapy in psychostimulant abuse. *Prog Brain Res* **172**:319-346.

Bubar MJ, Stutz SJ, Cunningham KA (2011) 5-HT(2C) receptors localize to dopamine and GABA neurons in the rat mesoaccumbens pathway. *PLoS One* **6**:e20508

Burbassi S, Cervo L (2008) Stimulation of serotonin(2C) receptors influences cocaine-seeking behavior in response to drug-associated stimuli in rats. *Psychopharmacology (Berl)* **196**:15-27.

Burke LK, Doslikova B, D'Agostino G, Greenwald-Yarnell M, Georgescu T, Chianese R, Martinez de Morentin PB, Ogunnowo-Bada E, Cansell C, Valencia-Torres L, Garfield AS, Apergis-Schoute J, Lam DD, Speakman JR, Rubinstein M, Low MJ, Rochford JJ, Myers MG, Evans ML, Heisler LK (2016) Sex difference in physical activity, energy expenditure and obesity driven by a subpopulation of hypothalamic POMC neurons. *Mol Metab* **5**:245-252.

Burns CM, Chu H, Rueter SM, Hutchinson LK, Canton H, Sanders-Bush E, Emeson RB (1997) Regulation of serotonin-2C receptor G-protein coupling by RNA editing. *Nature* **387**:303-308.

Buydens-Branchey L, Branchey M, Ferguson P, Hudson J, McKernin C (1997) The meta-chlorophenylpiperazine challenge test in cocaine addicts: Hormonal and psychological responses. *Biol Psychiat* **41**:1071-1086.

Campbell BM, Merchant KM (2003) Serotonin 2C receptors within the basolateral amygdala induce acute fear-like responses in an open-field environment. *Brain Res* **993**:1-9.



Canton H, Emeson RB, Barker EL, Backstrom JR, Lu JT, Chang MS, Sanders-Bush E (1996) Identification, molecular cloning, and distribution of a short variant of the 5-hydroxytryptamine<sub>2C</sub> receptor produced by alternative splicing. *Mol Pharmacol* **50**:799-807.

Carmel L, Koonin EV, Dracheva S (2012) Dependencies among editing sites in serotonin 2C receptor mRNA. *PLoS Comput Biol* **8**:e1002663.

Cathala A, Devroye C, Maitre M, Piazza PV, Abrous DN, Revest JM, Spampinato U (2015) Serotonin<sub>2C</sub> receptors modulate dopamine transmission in the nucleus accumbens independently of dopamine release: behavioral, neurochemical and molecular studies with cocaine. *Addiction biology* **20**:445-457.

Chinuck RS, Fortnum H, Baldwin DR (2007) Appetite stimulants in cystic fibrosis: a systematic review. *Journal of human nutrition and dietetics* **20**:526-537.

Christianson JP, Ragole T, Amat J, Greenwood BN, Strong PV, Paul ED, Fleshner M, Watkins LR, Maier SF (2010) 5-hydroxytryptamine 2C receptors in the basolateral amygdala are involved in the expression of anxiety after uncontrollable traumatic stress. *Biol Psychiatry* **67**:339-345.

Clifton PG, Lee MD, Dourish CT (2000) Similarities in the action of Ro 60-0175, a 5-HT<sub>2C</sub> receptor agonist and d-fenfluramine on feeding patterns in the rat. *Psychopharmacology (Berl)* **152**:256-267.

ClinicalTrials (2014)  
<https://clinicaltrials.gov/ct2/show/results/NCT00563706?term=vabicaserin&rank=2>.

Closse A (1983) [<sup>3</sup>H]Mesulergine, a selective ligand for serotonin-2 receptors. *Life Sci* **32**:2485-2495.

Conn PJ, Sanders-Bush E (1986) Agonist-induced phosphoinositide hydrolysis in choroid plexus. *J Neurochem* **47**:1754-1760.

Conn PJ, Sanders-Bush E, Hoffman BJ, Hartig PR (1986) A unique serotonin receptor in choroid plexus is linked to phosphatidylinositol turnover. *Proc Natl Acad Sci U S A* **83**:4086-4088.

Cremers TI, Giorgetti M, Bosker FJ, Hogg S, Arnt J, Mork A, Honig G, Bogeso KP, Westerink BH, den BH, Wikstrom HV, Tecott LH (2004) Inactivation of 5-HT<sub>2C</sub> receptors potentiates consequences of serotonin reuptake blockade. *Neuropsychopharmacology* **29**:1782-1789.

Cremers TI, Rea K, Bosker FJ, Wikstrom HV, Hogg S, Mork A, Westerink BH (2007) Augmentation of SSRI effects on serotonin by 5-HT<sub>2C</sub> antagonists: mechanistic studies. *Neuropsychopharmacology* **32**:1550-1557.

Cryan JF, Lucki I (2000) Antidepressant-like behavioral effects mediated by 5-Hydroxytryptamine(2C) receptors. *J Pharmacol Exp Ther* **295**:1120-1126.

Cunningham KA, Anastasio NC (2014) Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction. *Neuropharmacology* **76 Pt B**:460-478.

Cunningham KA, Anastasio NC, Fox RG, Stutz SJ, Bubar MJ, Swinford SE, Watson CS, Gilbertson SR, Rice KC, Rosenzweig-Lipson S, Moeller FG (2013) Synergism between a serotonin 5-HT<sub>2A</sub> receptor (5-HT<sub>2A</sub>R) antagonist and 5-HT<sub>2C</sub>R agonist suggests new pharmacotherapeutics for cocaine addiction. *ACS Chemical Neuroscience* **4**:110-121.

Cunningham KA, Fox RG, Anastasio NC, Bubar MJ, Stutz SJ, Moeller FG, Gilbertson SR, Rosenzweig-Lipson S (2011) Selective serotonin 5-HT<sub>2C</sub> receptor activation suppresses the reinforcing efficacy of cocaine and sucrose but differentially affects the incentive-salience value of cocaine- vs. sucrose-associated cues. *Neuropharmacology* **61**:513-523.

Dalton GL, Lee MD, Kennett GA, Dourish CT, Clifton PG (2006) Serotonin 1B and 2C receptor interactions in the modulation of feeding behaviour in the mouse. *Psychopharmacology (Berl)* **185**:45-57.

De Luca V, Muller DJ, Hwang R, Lieberman JA, Volavka J, Meltzer HY, Kennedy JL (2007) HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis. *Human Psychopharmacology-Clinical and Experimental* **22**: 463-467.

Di Giovanni G, De Deurwaerdere P (2016) New therapeutic opportunities for 5-HT receptor ligands in neuropsychiatric disorders. *Pharmacol Ther* **157** 125-162.

Di Giovanni G, De Deurwaerdere P, Di Mascio M, Di Matteo V, Esposito E, Spampinato U (1999) Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: A combined *in vivo* electrophysiological and microdialysis study. *Neuroscience* **91**:587-597.

Di Giovanni G, Di M, V, La G, V, Esposito E (2001) m-Chlorophenylpiperazine excites non-dopaminergic neurons in the rat substantia nigra and ventral tegmental area by activating serotonin-2C receptors. *Neuroscience* **103**:111-116.

Di Giovanni G, Di Matteo V, Pierucci M, Benigno A, Esposito E (2006) Central serotonin<sub>2C</sub> receptor: from physiology to pathology. *CurrTopMedChem* **6**:1909-1925.

Di Matteo V, Di Giovanni G, Di Mascio M, Esposito E (2000) Biochemical and electrophysiological evidence that RO 60-0175 inhibits mesolimbic dopaminergic function through serotonin(2C) receptors. *Brain Res* **865**:85-90.

Di Narzo AF, Kozlenkov A, Ge Y, Zhang B, Sanelli L, May Z, Li Y, Fouad K, Cardozo C, Koonin EV, Bennett DJ, Dracheva S (2015) Decrease of mRNA editing after spinal cord injury is caused by down-regulation of ADAR2 that is triggered by inflammatory response. *Scientific reports* **5**:12615.

Di Narzo AF, Kozlenkov A, Roussos P, Hao K, Hurd Y, Lewis DA, Sibille E, Siever LJ, Koonin E, Dracheva S (2014) A unique gene expression signature associated with serotonin 2C receptor RNA editing in the prefrontal cortex and altered in suicide. *Hum Mol Genet* **23**:4801-4813.

Dixon RAF, Kobilka BK, Strader DJ, Benovic JL, Dohlman HG, Frielle T, *et al.* (1986). CLONING OF THE GENE AND CDNA FOR MAMMALIAN BETA-ADRENERGIC-RECEPTOR AND HOMOLOGY WITH RHODOPSIN. *Nature* 321: 75-79.

Doods HN, Boddeke HO, Kalkman HO, Hoyer D, Mathy MJ, van Zwieten PA (1988). Central 5-HT<sub>1A</sub> receptors and the mechanism of the central hypotensive effect of (+)8-OH-DPAT, DP-5-CT, R28935 and urapidil. *J Cardiovasc Pharmacol*, **11**: 432-437.

Doyle VM, Creba JA, Rüegg UT, Hoyer D (1986). Serotonin increases the production of inositol phosphates and mobilises calcium via the 5-HT<sub>2</sub> receptor in A7r5 smooth muscle cells. *Naunyn-Schmiedeberg's Arch Pharmacol*, **333**: 98-103.

Dracheva S, Chin B, Haroutunian V (2008a) Altered serotonin 2C receptor RNA splicing in suicide: association with editing. *Neuroreport* **19**:379-382.

Dracheva S, Elhakem SL, Marcus SM, Siever LJ, McGurk SR, Haroutunian V (2003) RNA editing and alternative splicing of human serotonin 2C receptor in schizophrenia. *J Neurochem* **87**:1402-1412.

Dracheva S, Lyddon R, Barley K, Marcus SM, Hurd YL, Byne WM (2009) Editing of serotonin 2C receptor mRNA in the prefrontal cortex characterizes high-novelty locomotor response behavioral trait. *Neuropsychopharmacology* **34**:2237-2251.

Dracheva S, Patel N, Woo DA, Marcus SM, Siever LJ, Haroutunian V (2008b) Increased serotonin 2C receptor mRNA editing: a possible risk factor for suicide. *Mol Psychiatry* **13**:1001-1010.

Du Y, Davisson MT, Kafadar K, Gardiner K (2006) A-to-I pre-mRNA editing of the serotonin 2C receptor: comparisons among inbred mouse strains. *Gene* **382**:39-46.

Du Y, Stasko M, Costa AC, Davisson MT, Gardiner KJ, (2007) Editing of the serotonin 2C receptor pre-mRNA: Effects of the Morris Water Maze. *Gene* 391: 186-197.

Dunlop J, Marquis KL, Lim HK, Leung L, Kao J, Cheesman C, Rosenzweig-Lipson S (2006) Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909; therapeutic potential in multiple indications. *CNS Drug Rev* **12**:167-177.

Dunlop J, Sabb AL, Mazandarani H, Zhang J, Kalgaonker S, Shukhina E, Sukoff S, Vogel RL, Stack G, Schechter L, Harrison BL, Rosenzweig-Lipson S (2005) WAY-163909 ((7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole): A novel 5-HT2C receptor selective agonist with anorectic activity. *J Pharmacol Exp Ther* **313**:862-869.

Dunlop J, Watts SW, Barrett JE, Coupet J, Harrison B, Mazandarani H, Nawoschik S, Pangalos MN, Ramamoorthy S, Schechter L, Smith D, Stack G, Zhang J, Zhang G, Rosenzweig-Lipson S (2011) Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist. *J Pharmacol Exp Ther* **337**:673-680.

Eisai (2014) (<http://www.eisai.com/news/news201465.html>).

EMA/633676/2014, EPAR summary for the public: Valdoxan, agomelatine.

EMA/695134/2016, EPAR summary for the public: Thymanax, agomelatine

Engel G, Göthert M, Hoyer D, Schlicker E, Hillenbrand K (1986) Identity of inhibitory presynaptic 5-hydroxytryptamine (5-HT) autoreceptors in the rat brain cortex with 5-HT<sub>1B</sub> binding sites. *Naunyn-Schmied. Arch. Pharmacol.* 332: 1-7.

Engel G, Hoyer D, Berthold R, Wagner H (1981) (+/-)[125Iodo] cyanopindolol, a new ligand for beta-adrenoceptors: identification and quantitation of subclasses of beta-adrenoceptors in guinea pig. *Naunyn Schmiedebergs Arch Pharmacol* 317: 277-285.

Engel G, Hoyer D, Kalkman HO, Wick MB (1984) Identification of 5HT<sub>2</sub>- receptors on longitudinal muscle of the guinea pig ileum. *J.Recept.Res.* 4: 113-126.

Enz A, Donatsch P, Nordmann R (1984) Dopaminergic properties of mesulergine (CU 32-085) and its metabolites. *J.Neural Transm.* 60: 225- 238.

Fargin A, Raymond JR, Lohse MJ, Kobilka BK, Caron MG, Lefkowitz RJ (1988) THE GENOMIC CLONE G-21 WHICH RESEMBLES A BETA-ADRENERGIC-RECEPTOR SEQUENCE ENCODES THE 5-HT<sub>1A</sub> RECEPTOR. *Nature* 335: 358-360.

FDA (2012)  
<http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm309993.htm>).

Filip M, Cunningham KA (2002) Serotonin 5-HT<sub>2C</sub> receptors in nucleus accumbens regulate expression of the hyperlocomotive and discriminative stimulus effects of cocaine. *Pharmacol Biochem Behav* 71:745-756.

Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW (2000) Possible role of valvular serotonin 5-HT<sub>2B</sub> receptors in the cardiopathy associated with fenfluramine. *Mol Pharmacol* 57:75-81.

Fitzgerald LW, Iyer G, Conklin DS, Krause CM, Marshall A, Patterson JP, Tran DP, Jonak GJ, Hartig PR (1999) Messenger RNA editing of the human serotonin 5-HT<sub>2C</sub> receptor. *Neuropsychopharmacology* 21:82S-90S.

Fletcher PJ, Grottick AJ, Higgins GA (2002a) Differential effects of the 5-HT<sub>2A</sub> receptor antagonist M100,907 and the 5-HT<sub>2C</sub> receptor antagonist SB242,084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding. *Neuropsychopharmacology* 27:576-586.

Fletcher PJ, Korth KM, Robinson SR, Baker GB (2002b) Multiple 5-HT receptors are involved in the effects of acute MDMA treatment: studies on locomotor activity and responding for conditioned reinforcement. *Psychopharmacology (Berl)* 162:282-291.

Fletcher PJ, Chintoh AF, Sinyard J, Higgins GA (2004) Injection of the 5-HT<sub>2C</sub> receptor agonist Ro60-0175 into the ventral tegmental area reduces cocaine-induced locomotor activity and cocaine self-administration. *Neuropsychopharmacology* **29**:308-318.

Fletcher PJ, Rizos Z, Sinyard J, Tampakeras M, Higgins GA (2008) The 5-HT<sub>2C</sub> receptor agonist RO 60-0175 reduces cocaine self-administration, reinstatement induced by the stressor yohimbine and contextual cues. *Neuropsychopharmacology* **33**:1402-1412.

Fletcher PJ, Rizos Z, Noble K, Higgins GA (2011) Impulsive action induced by amphetamine, cocaine and MK801 is reduced by 5-HT<sub>2C</sub> receptor stimulation and 5-HT<sub>2A</sub> receptor blockade. *Neuropharmacology* **61**:468-477.

Fletcher PJ, Rizos Z, Noble K, Soko AD, Sileniaks LB, Le AD, Higgins GA (2012) Effects of the 5-HT<sub>2C</sub> receptor agonist Ro60-0175 and the 5-HT<sub>2A</sub> receptor antagonist M100907 on nicotine self-administration and reinstatement. *Neuropharmacology* **62**:2288-2298.

Flomen R, Knight J, Sham P, Kerwin R, Makoff A (2004) Evidence that RNA editing modulates splice site selection in the 5-HT<sub>2C</sub> receptor gene. *Nucleic Acids Res* **32**:2113-2122.

Foguet M, Hoyer D, Pardo LA, Parekh A, Kluxen FW, Kalkman HO, Stühmer W, Lübbert H (1992a) Cloning and functional characterization of the rat stomach fundus serotonin receptor. *EMBO J* **11**:3481-3487.

Foguet M, Nguyen H, Le H, Lübbert H, (1992b) Structure of the mouse 5-HT<sub>1C</sub>, 5-HT<sub>2</sub> and stomach fundus serotonin receptor genes. *Neuroreport* **3**: 345-348.

Fouad K, Rank MM, Vavrek R, Murray KC, Sanelli L, Bennett DJ (2010) Locomotion After Spinal Cord Injury Depends on Constitutive Activity in Serotonin Receptors. *J Neurophysiol* **104**: 2975-2984.

Gaddum JH, Picarelli ZP, (1957) Two kinds of tryptamine receptor. *Br. J. Pharmacol. Chemother.* **12**: 323-328.

Gatch MB (2003) Discriminative stimulus effects of m-chlorophenylpiperazine as a model of the role of serotonin receptors in anxiety. *Life Sci* **73**:1347-1367.

Gautron L, Elmquist JK, Williams KW (2015) Neural control of energy balance: translating circuits to therapies. *Cell* **161**:133-145.

Gavarini S, Becamel C, Altier C, Lory P, Poncet J, Wijnholds J, Bockaert J, Marin P (2006) Opposite effects of PSD-95 and MPP3 PDZ proteins on serotonin 5-hydroxytryptamine<sub>2C</sub> receptor desensitization and membrane stability. *Molecular Biology of the Cell* **17**:4619-4631.

Giger RKA, & Engel G (2006). Albert Hofmann's pioneering work on ergot alkaloids and its impact on the search of novel drugs at Sandoz, a predecessor company of novartis - Dedicated to Dr. Albert Hofmann on the occasion of his 100th birthday. *Chimia* **60**: 83-87.



Gobert A, Rivet JM, Lejeune F, Newman-Tancredi A, Adhumeau-Auclair A, Nicolas JP, Cistarelli L, Melon C, Millan MJ (2000) Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat. *Synapse* **36**:205-221.

Gozlan H, el Mestikawy S, Pichat L, Glowinski J, Hamon M, (1983) Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT. *Nature* **305**: 140-142.

Grauer SM, Graf R, Navarra R, Sung A, Logue SF, Stack G, Huselton C, Liu Z, Comery TA, Marquis KL, Rosenzweig-Lipson S (2009) WAY-163909, a 5-HT<sub>2C</sub> agonist, enhances the preclinical potency of current antipsychotics. *Psychopharmacology (Berl)* **204**:37-48.

Graves SM, Napier TC (2012) SB 206553, a putative 5-HT<sub>2C</sub> inverse agonist, attenuates methamphetamine-seeking in rats. *BMC Neurosci* **13**:65.

Grottick AJ, Fletcher PJ, Higgins GA (2000) Studies to investigate the role of 5-HT<sub>2C</sub> receptors on cocaine- and food-maintained behavior. *J Pharmacol Exp Ther* **295**:1183-1191.

Grottick AJ, Corrigall WA, Higgins GA (2001) Activation of 5-HT<sub>2C</sub> receptors reduces the locomotor and rewarding effects of nicotine. *Psychopharmacology (Berl)* **157**:292-298.

Grottick AJ, Whelan K, Sanabria EK, Behan DP, Morgan M, Sage C (2015) Investigating interactions between phentermine, dexfenfluramine, and 5-HT<sub>2C</sub> agonists, on food intake in the rat. *Psychopharmacology (Berl)* **232**:1973-1982.

Gurevich I, Tamir H, Arango V, Dwork AJ, Mann JJ, Schmauss C (2002) Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. *Neuron* **34**:349-356.

Hackler EA, Airey DC, Shannon CC, Sodhi MS, Sanders-Bush E (2006) 5-HT<sub>2C</sub> receptor RNA editing in the amygdala of C57BL/6J, DBA/2J, and BALB/cJ mice. *Neurosci Res* **55**:96-104.

Hackler EA, Turner GH, Gresch PJ, Sengupta S, Deutch AY, Avison MJ, Gore JC, Sanders-Bush E, (2007) 5-Hydroxytryptamine<sub>2C</sub> receptor contribution to m-chlorophenylpiperazine and N-methyl-beta-carboline-3-carboxamide-induced anxiety-like behavior and limbic brain activation. *J Pharmacol Exp Ther* **320**: 1023-1029.

Halford JC, Blundell JE (2000) Separate systems for serotonin and leptin in appetite control. *Ann Med* **32**:222-232.

Halford JC, Lawton CL, Blundell JE (1997) The 5-HT<sub>2</sub> receptor agonist MK-212 reduces food intake and increases resting but prevents the behavioural satiety sequence. *Pharmacol Biochem Behav* **56**:41-46.

Halford JC, Wanninayake SC, Blundell JE (1998) Behavioral satiety sequence (BSS) for the diagnosis of drug action on food intake. *Pharmacol Biochem Behav* **61**:159-168.

- Harada K, Aota M, Inoue T, Matsuda R, Mihara T, Yamaji T, Ishibashi K, Matsuoka N (2006) Anxiolytic activity of a novel potent serotonin 5-HT<sub>2C</sub> receptor antagonist FR260010: a comparison with diazepam and buspirone. *Eur J Pharmacol* **553**:171-184.
- Hartig PR, Hoyer D, Humphrey PP, Martin GR, (1996) Alignment of receptor nomenclature with the human genome: classification of 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptor subtypes. *Trends Pharmacol.Sci.* 17: 103-105.
- Harvey-Lewis C, Li Z, Higgins GA, Fletcher PJ (2016) The 5-HT<sub>2C</sub> receptor agonist lorcaserin reduces cocaine self-administration, reinstatement of cocaine-seeking and cocaine induced locomotor activity. *Neuropharmacology* **101**:237-245.
- Hayasaka Y, Purgato M, Magni LR, Ogawa Y, Takeshima N, Cipriani A, Barbui C, Leucht S, Furukawa TA (2015) Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. *J Affect Disord* **180**:179-184.
- Heisler LK, Tecott LH (2000) A paradoxical locomotor response in serotonin 5-HT<sub>2C</sub> receptor mutant mice. *J Neurosci* **20**:RC71.
- Heisler LK, Chu HM, Tecott LH (1998) Epilepsy and obesity in serotonin 5-HT<sub>2C</sub> receptor mutant mice. *Annals of the New York Academy of Sciences* **861**:74-78.
- Heisler LK, Cowley MA, Tecott LH, Fan W, Low MJ, Smart JL, Rubinstein M, Tatro JB, Marcus JN, Holstege H, Lee CE, Cone RD, Elmquist JK (2002) Activation of central melanocortin pathways by fenfluramine. *Science* **297**:609-611.
- Heisler LK, Pronchuk N, Nonogaki K, Zhou L, Raber J, Tung L, Yeo GS, O'Rahilly S, Colmers WF, Elmquist JK, Tecott LH (2007a) Serotonin activates the hypothalamic-pituitary-adrenal axis via serotonin 2C receptor stimulation. *J Neurosci* **27**:6956-6964.
- Heisler LK, Zhou L, Bajwa P, Hsu J, Tecott LH (2007b) Serotonin 5-HT<sub>2C</sub> receptors regulate anxiety-like behavior. *Genes Brain Behav* **6**:491-496.
- Herrick-Davis K (2013) Functional significance of serotonin receptor dimerization. *Exp Brain Res* **230**:375-386.
- Herrick-Davis K, Farrington DT (2011) 5-HT<sub>2C</sub> receptor dimerization, in *5-HT<sub>2C</sub> Receptors in the Pathophysiology of CNS Disease* (Di Giovanni G, Esposito E, Di Matteo V eds) pp 129-155, Humana Press.
- Herrick-Davis K, Grinde E, Niswender CM (1999) Serotonin 5-HT<sub>2C</sub> receptor RNA editing alters receptor basal activity: implications for serotonergic signal transduction. *J Neurochem* **73**:1711-1717.
- Herrick-Davis K, Grinde E, Teitler M (2000) Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine<sub>2C</sub> receptors. *J Pharmacol Exp Ther* **295**:226-232.

Herrick-Davis K, Grinde E, Mazurkiewicz JE (2004) Biochemical and biophysical characterization of serotonin 5-HT<sub>2C</sub> receptor homodimers on the plasma membrane of living cells. *Biochemistry* **43**:13963-13971.

Herrick-Davis K, Grinde E, Harrigan TJ, Mazurkiewicz JE (2005) Inhibition of serotonin 5-hydroxytryptamine<sub>2c</sub> receptor function through heterodimerization: receptor dimers bind two molecules of ligand and one G-protein. *J Biol Chem* **280**:40144-40151.

Herrick-Davis K, Weaver BA, Grinde E, Mazurkiewicz JE (2006) Serotonin 5-HT<sub>2C</sub> receptor homodimer biogenesis in the endoplasmic reticulum: real-time visualization with confocal fluorescence resonance energy transfer. *J Biol Chem* **281**:27109-27116.

Herrick-Davis K, Grinde E, Weaver BA (2007) Serotonin 5-HT<sub>2C</sub> receptor homodimerization is not regulated by agonist or inverse agonist treatment. *Eur J Pharmacol* **568**:45-53.

Herrick-Davis K, Grinde E, Lindsley T, Cowan A, Mazurkiewicz JE (2012) Oligomer size of the serotonin 5-hydroxytryptamine 2C (5-HT<sub>2C</sub>) receptor revealed by fluorescence correlation spectroscopy with photon counting histogram analysis: evidence for homodimers without monomers or tetramers. *J Biol Chem* **287**:23604-23614.

Herrick-Davis K, Grinde E, Cowan A, Mazurkiewicz JE (2013) Fluorescence correlation spectroscopy analysis of serotonin, adrenergic, muscarinic, and dopamine receptor dimerization: the oligomer number puzzle. *Mol Pharmacol* **84**:630-642.

Herrick-Davis K, Grinde E, Lindsley T, Teitler M, Mancina F, Cowan A, Mazurkiewicz JE (2015) Native Serotonin 5-HT<sub>2C</sub> Receptors Are Expressed as Homodimers on the Apical Surface of Choroid Plexus Epithelial Cells. *Mol Pharmacol* **87**:660-673.

Hewitt KN, Lee MD, Dourish CT, Clifton PG (2002) Serotonin 2C receptor agonists and the behavioural satiety sequence in mice. *Pharmacol Biochem Behav* **71**:691-700.

Hietala J, Kuonnamaki M, Palvimaki EP, Laakso A, Majasuo H, Syvalahti E (2001) Sertindole is a serotonin 5-HT<sub>2c</sub> inverse agonist and decreases agonist but not antagonist binding to 5-HT<sub>2c</sub> receptors after chronic treatment. *Psychopharmacology (Berl)* **157**:180-187.

Higgins GA, Sileniaks LB, Rossmann A, Rizos Z, Noble K, Soko AD, Fletcher PJ (2012) The 5-HT<sub>2c</sub> receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control. *Neuropsychopharmacology* **37**:1177-1191.

Higgs S, Cooper AJ, Barnes NM (2016) The 5-HT<sub>2C</sub> receptor agonist, lorcaserin, and the 5-HT<sub>6</sub> receptor antagonist, SB-742457, promote satiety; a microstructural analysis of feeding behaviour. *Psychopharmacology (Berl)* **233**:417-424.

Hjorth S, Carlsson A, Lindberg P, Sanchez D, Wilkström H, Arvidsson LE, Hacksell U, Nilsson JLG, (1982) 8-hydroxy-2-(di-n-propylamino)tetralin, 8-OH-DPAT, a potent and selective simplified ergot congener with central 5-HT-receptor stimulating activity.

J. Neural Transm. 55: 169-188.

Hoffman BJ, Mezey E (1989) Distribution of serotonin 5-HT<sub>1C</sub> receptor mRNA in adult rat brain. *FEBS Lett* **247**:453-462.

Howell LL, Cunningham KA (2015) Serotonin 5-HT<sub>2</sub> receptor interactions with dopamine function: implications for therapeutics in cocaine use disorder. *Pharmacol Rev* **67**:176-197.

Howes SR, Dalley JW, Morrison CH, Robbins TW, Everitt BJ (2000) Leftward shift in the acquisition of cocaine self-administration in isolation-reared rats: relationship to extracellular levels of dopamine, serotonin and glutamate in the nucleus accumbens and amygdala-striatal FOS expression. *Psychopharmacology (Berl)* **151**:55-63.

Hoyer D (1988a). Molecular pharmacology and biology of 5-HT<sub>1C</sub> receptors. *TIPS*, **9**: 89-94.

Hoyer D (1988b). Functional correlates to serotonin 5-HT<sub>1</sub> recognition sites. *J Rec Res*, **8**: 59-81.

Hoyer D, Middlemiss DN, (1989) Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain. *Trends Pharmacol.Sci.* 10: 130-132.

Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PPA (1994) VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). *Pharmacol Rev* **46**:157-204.

Hoyer D, Engel G, Berthold R, (1982) Binding characteristics of (+)-, (+/-)- and (-)-[<sup>125</sup>I]cyanopindolol to guinea-pig left ventricle membranes. *Naunyn Schmiedeberg's Arch Pharmacol* 318: 319-329.

Hoyer D, Engel G, Kalkman HO, (1985b) Characterization of the 5-HT<sub>1B</sub> recognition site in rat brain: binding studies with [<sup>125</sup>I]-iodocyanopindolol. *Eur.J.Pharmacol.* 118: 1-12.

Hoyer D, Engel G, Kalkman HO (1985a) Molecular pharmacology of 5-HT<sub>1</sub> and 5-HT<sub>2</sub> recognition sites in rat and pig brain membranes: radioligand binding studies with [<sup>3</sup>H]5-HT, [<sup>3</sup>H]8-OH-DPAT, (-)[<sup>125</sup>I]iodocyanopindolol, [<sup>3</sup>H]mesulergine and [<sup>3</sup>H]ketanserin. *Eur J Pharmacol*, **118**: 13-23.

Hoyer D, Hannon JP, Martin GR (2002) Molecular, pharmacological and functional diversity of 5-HT receptors. *Pharmacology Biochemistry and Behavior* **71**:533-554.

Hoyer D, Pazos A, Probst A, Palacios JM (1986a) Serotonin receptors in the human brain. II. Characterization and autoradiographic localization of 5-HT<sub>1C</sub> and 5-HT<sub>2</sub> recognition sites. *Brain Res* **376**:97-107.

Hoyer D, Pazos A, Probst A, Palacios JM, (1986b) Serotonin receptors in the human brain. I. Characterization and autoradiographic localization of 5-HT<sub>1A</sub> recognition sites.

Apparent absence of 5-HT<sub>1B</sub> recognition sites. *Brain Research* 376: 85-96.

Hoyer D, Srivatsa S, Pazos A, Engel G, Palacios JM, (1986c) [125I]LSD labels 5-HT<sub>1C</sub> recognition sites in pig choroid plexus membranes. Comparison with [3H]mesulergine and [3H]5-HT binding. *Neurosci.Lett.* 69: 269-274.

Hoyer D, Karpf A (1988). [125I]SCH 23982, a "selective" D1 receptor antagonist, labels with high affinity 5-HT<sub>1C</sub> sites in pig choroid plexus. *Eur J Pharmacol*, **150**: 181-184.

Hoyer D, Schoeffter P (1988). 5-HT<sub>1D</sub> receptors inhibit forskolin-stimulated adenylate cyclase activity in calf substantia nigra. *Eur J Pharmacol*, **147**: 145-147.

Hoyer D, Waeber C, Schoeffter P, Palacios JM, Dravid A (1989) 5-HT<sub>1C</sub> receptor-mediated stimulation of inositol phosphate production in pig choroid plexus. A pharmacological characterization. *Naunyn Schmiedebergs Arch Pharmacol* **339**:252-258.

Humphrey PPA, Hartig PR, Hoyer D (1993). A new nomenclature for 5-HT receptors. *Trends Pharmacol Sci*, **14**: 233-236.

Husch A, Van Patten G N, Hong DN, Scaperotti MM, Cramer N, Harris-Warrick RM (2012) Spinal Cord Injury Induces Serotonin Supersensitivity without Increasing Intrinsic Excitability of Mouse V2a Interneurons. *The Journal of Neuroscience*, **32**:13145–13154

Isaac M (2005) Serotonergic 5-HT<sub>2C</sub> Receptors as a Potential Therapeutic Target for the Design Antiepileptic Drugs. *Current Topics in Medicinal Chemistry* **5**:59-67.

Ishii Y, Blundell JE, Halford JC, Rodgers RJ (2003) Palatability, food intake and the behavioural satiety sequence in male rats. *Physiol Behav* **80**:37-47.

Iwamoto K, Kato T (2003) RNA editing of serotonin 2C receptor in human postmortem brains of major mental disorders. *Neurosci Lett* **346**:169-172.

Iwamoto K, Bundo M, Kato T (2011) RNA editing of 5-HT<sub>2C</sub> receptor and neuropsychiatric diseases, in *5-HT<sub>2C</sub> Receptors in the Pathophysiology of CNS Disease* (Di Giovanni G, Esposito E, Di Matteo V eds) pp 157-167, Humana Press.

Iwamoto K, Nakatani N, Bundo M, Yoshikawa T, Kato T, (2005) Altered RNA editing of serotonin 2C receptor in a rat model of depression. *Neurosci.Res.* 53: 69-76.

Jakus R, Graf M, Juhasz G, Gerber K, Levay G, Halasz P, Bagdy G (2003) 5-HT<sub>2C</sub> receptors inhibit and 5-HT<sub>1A</sub> receptors activate the generation of spike-wave discharges in a genetic rat model of absence epilepsy. *Exp Neurol* **184**:964-972.

Jenck F, Bos M, Wichmann J, Stadler H, Martin JR, Moreau JL (1998) The role of 5-HT<sub>2C</sub> receptors in affective disorders. *Expert Opin Investig Drugs* **7**:1587-1599.



Ji SP, Zhang Y, Van CJ, Jiang W, Liao M, Li L, Wan Q, Backstrom JR, Zhang X (2006) Disruption of PTEN coupling with 5-HT<sub>2C</sub> receptors suppresses behavioral responses induced by drugs of abuse. *NatMed* **12**:324-329.

Julius D, MacDermott AB, Axel R, Jessell JM (1988) Molecular characterization of a functional cDNA encoding the serotonin 1C receptor. *Science* **241**:558-564.

Julius D, Huang KN, Livelli TJ, Axel R, Jessell TM (1989) The 5HT<sub>2</sub> receptor defines a family of structurally distinct but functionally conserved serotonin receptors. *Proc Natl Acad Sci USA* **87**, 928-932.

Juruena MF, de Sena EP, de Oliveira IR (2011) Sertindole in the management of schizophrenia. *Journal of central nervous system disease* **3**:75-85.

Kahn RS, Wetzler S (1991) m-Chlorophenylpiperazine as a probe of serotonin function. *BiolPsychiat* **30**:1139-1166.

Kalkman HO, Engel G, Hoyer D (1984). Three distinct subtypes of serotonergic receptors mediate the triphasic blood pressure response to 5-HT in rats. *J Hypertension*, **2**: 143-145.

Kalkman HO, Engel G, Hoyer D, (1986) Inhibition of 5- carboxamidotryptamine-induced relaxation of guinea-pig ileum correlates with [<sup>125</sup>I]LSD binding. *Eur.J.Pharmacol.* **129**: 139-145.

Kamal M, Gbahou F, Guillaume JL, Daulat AM, Benleulmi-Chaachoua A, Luka M, Chen P, Kalbasi Anaraki D, Baroncini M, Mannoury la Cour C, Millan MJ, Prevoit V, Delagrangé P, Jockers R (2015) Convergence of melatonin and serotonin (5-HT) signaling at MT<sub>2</sub>/5-HT<sub>2C</sub> receptor heteromers. *J Biol Chem* **290**:11537-11546.

Kasper JM, Tikamdas R, Kim MS, Macfadyen K, Aramini R, Ladd J, Bisceglia S, Booth R, Peris J (2013) The serotonin-2 receptor modulator, (-)-trans-PAT, decreases voluntary ethanol consumption in rats. *Eur J Pharmacol* **718**:98-104.

Kennett G, Lightowler S, Trail B, Bright F, Bromidge S (2000) Effects of RO 60 0175, a 5-HT<sub>2C</sub> receptor agonist, in three animal models of anxiety. *Eur J Pharmacol* **387**:197-204.

Kennett GA, Curzon G (1988) Evidence that hypophagia induced by mCPP and TFMPP requires 5-HT<sub>1C</sub> and 5-HT<sub>1B</sub> receptors; Hypophagia induced by RU 24969 only requires 5-HT<sub>1B</sub> receptors. *Psychopharmacology* **96**:93-100.

Kennett GA, Pittaway K, Blackburn TP (1994) Evidence that 5-HT<sub>2C</sub> receptor antagonists are anxiolytic in the rat Geller-Seifter model of anxiety. *Psychopharmacology (Berl)* **114**:90-96.

Kennett GA, Whitton P, Shah K, Curzon G (1989) Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT<sub>1C</sub> receptor antagonists. *Eur J Pharmacol* **164**:445-454.

Kennett GA, Wood MD, Bright F, Cilia J, Piper DC, Gager T, Thomas D, Baxter GS, Forbes IT, Ham P, Blackburn TP (1996) *In vitro* and *in vivo* profile of SB 206553, a potent 5-HT<sub>2C</sub>/5-HT<sub>2B</sub> receptor antagonist with anxiolytic-like properties. *Br J Pharmacol* **117**:427-434.

Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V, Avenell KY, Stean T, Upton N, Bromidge S, Forbes IT, Brown AM, Middlemiss DN, Blackburn TP (1997) SB 242084, a selective and brain penetrant 5-HT<sub>2C</sub> receptor antagonist. *Neuropharmacology* **36**:609-620.

Kirk SL, Glazebrook J, Grayson B, Neill JC, Reynolds GP (2009) Olanzapine-induced weight gain in the rat: role of 5-HT<sub>2C</sub> and histamine H<sub>1</sub> receptors. *Psychopharmacology (Berl)* **207**:119-125.

Kishore S, Stamm S (2006) The snoRNA HBII-52 regulates alternative splicing of the serotonin receptor 2C. *Science* **311**:230-232.

Kishore S, Khanna A, Zhang Z, Hui J, Balwierz PJ, Stefan M, Beach C, Nicholls RD, Zavolan M, Stamm S (2010) The snoRNA MBII-52 (SNORD 115) is processed into smaller RNAs and regulates alternative splicing. *Hum Mol Genet* **19**:1153-1164.

Kleene R, Chaudhary H, Karl N, Katic J, Kotarska A, Guitart K, Loers G, Schachner M (2015) Interaction between CHL1 and serotonin receptor 2c regulates signal transduction and behavior in mice. *J Cell Sci* **128**:4642-4652.

Labasque M, Reiter E, Becamel C, Bockaert J, Marin P (2008) Physical interaction of calmodulin with the 5-hydroxytryptamine<sub>2C</sub> receptor C-terminus is essential for G protein-independent, arrestin-dependent receptor signaling. *Mol Biol Cell* **19**:4640-4650.

Laduron PM, (1984) Criteria for receptor sites in binding studies. *Biochem Pharmacol.* **33**: 833-839.

Lam DD, Przydzial MJ, Ridley SH, Yeo GSH, Rochford JJ, O'Rahilly S, Heisler LK (2008) Serotonin 5-HT<sub>2C</sub> receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors. *Endocrinology* **149**:1323-1328.

Lee MA, Meltzer HY (1994) Blunted oral body temperature response to MK-212 in cocaine addicts. *Drug Alcohol Depend* **35**:217-222.

Lefkowitz RJ, (2004) Historical review: a brief history, personal retrospective of seven-transmembrane receptors. *Trends Pharmacol Sci* **25**: 413-422.

Leggio GM, Cathala A, Neny M, Rouge-Pont F, Drago F, Piazza PV, Spampinato U (2009) *In vivo* evidence that constitutive activity of serotonin<sub>2C</sub> receptors in the medial prefrontal cortex participates in the control of dopamine release in the rat nucleus accumbens: differential effects of inverse agonist versus antagonist. *J Neurochem* **111**:614-623.

- Levin ED, Johnson JE, Slade S, Wells C, Cauley M, Petro A, Rose JE (2011) Lorcaserin, a 5-HT<sub>2C</sub> agonist, decreases nicotine self-administration in female rats. *J Pharmacol Exp Ther* **338**:890-896.
- Lindvall-Axelsson M, Mathew C, Nilsson C, Owman C, (1988) Effect of 5-hydroxytryptamine on the rate of cerebrospinal fluid production in rabbit. *Exp.Neurol.* 99: 362-368.
- Liu S, Lane SD, Schmitz JM, Waters AJ, Cunningham KA, Moeller FG (2011) Relationship between attentional bias to cocaine-related stimuli and impulsivity in cocaine-dependent subjects. *Am J Drug Alcohol Abuse* **37**:117-122.
- Liu S, Lane SD, Schmitz JM, Green CE, Cunningham KA, Moeller FG (2012) Increased intra-individual reaction time variability in cocaine-dependent subjects: role of cocaine-related cues. *Addict Behav* **37**:193-197.
- Liu Y, Emeson RB, Samuel CE (1999) Serotonin-2C receptor pre-mRNA editing in rat brain and in vitro by splice site variants of the interferon-inducible double-stranded RNA-specific adenosine deaminase ADAR1. *J Biol Chem* **274**:18351-18358.
- Lopez-Gimenez JF, Mengod G, Palacios JM, Vilaro MT (2001) Regional distribution and cellular localization of 5-HT<sub>2C</sub> receptor mRNA in monkey brain: comparison with [3H]mesulergine binding sites and choline acetyltransferase mRNA. *Synapse* **42**:12-26.
- Lowy MT, Meltzer HY (1988) Stimulation of serum cortisol and prolactin secretion in humans by MK-212, a centrally active serotonin agonist. *Biol Psychiatry* **23**:818-828.
- Lubbert H, Hoffman BJ, Snutch TP, van Dyke T, Levine AJ, Hartig PR, Lester HA, Davidson N (1987) cDNA cloning of a serotonin 5-HT<sub>1C</sub> receptor by electrophysiological assays of mRNA-injected *Xenopus* oocytes. *Proc Natl Acad Sci U S A* **84**:4332-4336.
- Lucki I (1998) The spectrum of behaviors influenced by serotonin. *Biol Psychiatry* **44**:151-162.
- Lyddon R, Dwork AJ, Keddache M, Siever LJ, Dracheva S (2013) Serotonin 2c receptor RNA editing in major depression and suicide. *The world journal of biological psychiatry* **14**:590-601.
- Maillet JC, Zhang Y, Li X, Zhang X (2008) PTEN-5-HT<sub>2C</sub> coupling: a new target for treating drug addiction. *Prog Brain Res* **172**:407-420.
- Manvich DF, Kimmel HL, Cooper DA, Howell LL (2012a) The serotonin 2C receptor antagonist SB 242084 exhibits abuse-related effects typical of stimulants in squirrel monkeys. *J Pharmacol Exp Ther* **342**:761-769.
- Manvich DF, Kimmel HL, Howell LL (2012b) Effects of serotonin 2C receptor agonists on the behavioral and neurochemical effects of cocaine in squirrel monkeys. *J Pharmacol Exp Ther* **341**:424-434.

- Marion S, Weiner DM, Caron MG (2004) RNA editing induces variation in desensitization and trafficking of 5-hydroxytryptamine 2c receptor isoforms. *J Biol Chem* **279**:2945-2954.
- Markstein R, (1983) Mesulergine and its 1,20-N,N-bidemethylated metabolite interact directly with D1- and D2-receptors. *Eur J.Pharmacol.* 95: 101-107.
- Markstein R, Hoyer D, Engel G, (1986) 5-HT<sub>1A</sub>-receptors mediate stimulation of adenylate cyclase in rat hippocampus. *Naunyn Schmiedebergs Arch Pharmacol* 333: 335-341.
- Marquis KL, Sabb AL, Logue SF, Brennan JA, Piesla MJ, Comery TA, Grauer SM, Ashby CR, Jr., Nguyen HQ, Dawson LA, Barrett JE, Stack G, Meltzer HY, Harrison BL, Rosenzweig-Lipson S (2007) WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[ 6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. *J Pharmacol Exp Ther* **320**:486-496.
- Martin CB, Hamon M, Lanfumey L, Mongeau R (2014) Controversies on the role of 5-HT<sub>2C</sub> receptors in the mechanisms of action of antidepressant drugs. *Neurosci Biobehav Rev* **42**:208-223.
- Martin CB, Martin VS, Trigo JM, Chevarin C, Maldonado R, Fink LH, Cunningham KA, Hamon M, Lanfumey L, Mongeau R (2015) 5-HT<sub>2C</sub> receptor desensitization moderates anxiety in 5-HT<sub>2C</sub> deficient mice: from behavioral to cellular evidence. *The international journal of neuropsychopharmacology* **18**:1-12.
- Martin CB, Ramond F, Farrington DT, Aguiar AS, Jr., Chevarin C, Berthiau AS, Caussanel S, Lanfumey L, Herrick-Davis K, Hamon M, Madjar JJ, Mongeau R (2013) RNA splicing and editing modulation of 5-HT<sub>2C</sub> receptor function: relevance to anxiety and aggression in VGV mice. *Mol Psychiatry* **18**:656-665.
- Martin JR, Bos M, Jenck F, Moreau JL, Mutel V, Sleight AJ, Wichmann J, Andrews JS, Berendsen HHG, Broekkamp CLE, Ruigt GSF, Kohler C, Van Delft AML (1998) 5-HT<sub>2C</sub> receptor agonists: Pharmacological characteristics and therapeutic potential. *Journal of Pharmacology & Experimental Therapeutics* **286**:913-924.
- Maurel S, De Vry J, Schreiber R (1999) 5-HT receptor ligands differentially affect operant oral self-administration of ethanol in the rat. *Eur J Pharmacol* **370**:217-223.
- Meltzer HY (1999) The Role of Serotonin in Antipsychotic Drug Action. *Neuropsychopharmacology* **21**:106S-115S.
- Mengod G, Nguyen H, Le H, Waeber C, Lübbert H, Palacios JM (1990) The distribution and cellular localization of the serotonin 1C receptor mRNA in the rodent brain examined by *in situ* hybridization histochemistry. Comparison with receptor binding distribution. *Neuroscience* **35**:577-591.
- Middlemiss DN, Fozard JR, (1983) 8-Hydroxy-2-(di-n-propylamino)- tetralin discriminates

between subtypes of the 5-HT<sub>1</sub> recognition site. *Eur J Pharmacol* **90**: 151-153.

Milatovich A, Hsieh CL, Bonaminio G, Tecott L, Julius D, Francke U (1992) Serotonin receptor 1c gene assigned to X chromosome in human (band q24) and mouse (bands D-F4). *Hum Mol Genet* **1**:681-684.

Millan MJ (2003) The neurobiology and control of anxious states. *Prog Neurobiol* **70**:83-244.

Millan MJ (2005) Serotonin 5-HT<sub>2C</sub> receptors as a target for the treatment of depressive, anxious states: focus on novel therapeutic strategies. *Therapie* **60**:441-460.

Millan MJ, Brocco M, Gobert A, Dekeyne A (2005) Anxiolytic properties of agomelatine, an antidepressant with melatonergic and serotonergic properties: role of 5-HT<sub>2C</sub> receptor blockade. *Psychopharmacology (Berl)* **177**:448-458.

Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Rivet JM, Cussac D (2003) The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine<sub>2C</sub> receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. *J Pharmacol Exp Ther* **306**:954-964.

Millan MJ, Marin P, Bockaert J, Mannoury la Cour C (2008) Signaling at G-protein-coupled serotonin receptors: recent advances and future research directions. *Trends Pharmacol Sci* **29**:454-464.

Millan MJ, Marin P, Kamal M, Jockers R, Chanrion B, Labasque M, Bockaert J, Mannoury la Cour C (2011) The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT<sub>2C</sub> receptors. *IntJNeuropsychopharmacol* **14**:768-783.

Miller KJ (2005) Serotonin 5-HT<sub>2C</sub> receptor agonists: potential for the treatment of obesity. *Mol Interv* **5**:282-291.

Molineaux SM, Jessell TM, Axel R, Julius D (1989) 5-HT<sub>1c</sub> receptor is a prominent serotonin receptor subtype in the central nervous system. *Proc Natl Acad Sci USA* **86**:6793-6797.

Moreau JL, Bos M, Jenck F, Martin JR, Mortas P, Wichmann J (1996) 5HT<sub>2C</sub> receptor agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats. *European neuropsychopharmacology* **6**:169-175.

Moya PR, Berg KA, Gutierrez-Hernandez MA, Saez-Briones P, Reyes-Parada M, Cassels BK, Clarke WP (2007) Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)<sub>2A</sub> and 5-HT<sub>2C</sub> receptors. *J Pharmacol Exp Ther* **321**:1054-1061.



Murotani T, Ishizuka T, Isogawa Y, Karashima M, Yamatodani A (2011) Possible involvement of serotonin 5-HT<sub>2</sub> receptor in the regulation of feeding behavior through the histaminergic system. *Neuropharmacology* **61**:228-233.

Murray KC, Nakae A, Stephens MJ, Rank M, D'Amico J, Harvey PJ, Li X, Harris RLW, Ballou EW, Anell R, Heckman CJ, Mashimo T, Vavre R, Sanelli L, Gorassini MA, Bennett DJ, Fouad K (2010) Recovery of motoneuron and locomotor function after spinal cord injury depends on constitutive activity in 5-HT<sub>2C</sub> receptors. *Nature Med.* **16**, 694–700

Murray KC, Stephens MJ, Ballou EW, Heckman CJ, Bennett DJ (2011) Motoneuron Excitability and Muscle Spasms Are Regulated by 5-HT<sub>2C</sub> and 5-HT<sub>2B</sub> Receptor Activity. *Neurophysiol* **105**:731-748

Navailles S, De Deurwaerdere P, Porras G, Spampinato U (2004) In vivo evidence that 5-HT<sub>2C</sub> receptor antagonist but not agonist modulates cocaine-induced dopamine outflow in the rat nucleus accumbens and striatum. *Neuropsychopharmacology* **29**:319-326.

Navailles S, Moison D, Cunningham KA, Spampinato U (2008) Differential regulation of the mesoaccumbens dopamine circuit by serotonin<sub>2C</sub> receptors in the ventral tegmental area and the nucleus accumbens: an in vivo microdialysis study with cocaine. *Neuropsychopharmacology* **33**:237-246.

Navailles S, Lagiere M, Le Moine C, De Deurwaerdere P (2013a) Role of 5-HT<sub>2C</sub> receptors in the enhancement of c-Fos expression induced by a 5-HT<sub>2B/2C</sub> inverse agonist and 5-HT<sub>2</sub> agonists in the rat basal ganglia. *Exp Brain Res* **230**:525-535.

Navailles S, Lagiere M, Roumegous A, Polito M, Boujema MB, Cador M, Dunlop J, Chesselet MF, Millan MJ, De Deurwaerdere P (2013b) Serotonin<sub>2C</sub> ligands exhibiting full negative and positive intrinsic activity elicit purposeless oral movements in rats: distinct effects of agonists and inverse agonists in a rat model of Parkinson's disease. *The international journal of neuropsychopharmacology* / **16**:593-606.

Neisewander JL, Acosta JI (2007) Stimulation of 5-HT<sub>2C</sub> receptors attenuates cue and cocaine-primed reinstatement of cocaine-seeking behavior in rats. *Behav Pharmacol* **18**:791-800.

Nic Dhonnchadha BA, Bourin M, Hascoet M (2003) Anxiolytic-like effects of 5-HT<sub>2</sub> ligands on three mouse models of anxiety. *Behav Brain Res* **140**:203-214.

Nichols DE (2004) Hallucinogens. *Pharmacol Ther* **101**:131-181.

Niswender CM, Copeland SC, Herrick-Davis K, Emeson RB, Sanders-Bush E (1999) RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. *J Biol Chem* **274**:9472-9478.

Niswender CM, Herrick-Davis K, Dilley GE, Meltzer HY, Overholser JC, Stockmeier CA, Emeson RB, Sanders-Bush E (2001) RNA editing of the human serotonin 5-HT<sub>2C</sub> receptor: Alterations in suicide and implications for serotonergic pharmacotherapy. *Neuropsychopharmacology* **24**:478-491.

Nonogaki K, Ohba Y, Sumii M, Oka Y (2008) Serotonin systems upregulate the expression of hypothalamic NUCB2 via 5-HT<sub>2C</sub> receptors and induce anorexia via a leptin-independent pathway in mice. *Biochem Biophys Res Commun* **372**:186-190.

Nonogaki K, Strack AM, Dallman MF, Tecott LH (1998) Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT<sub>2C</sub> receptor gene. *Nature Medicine* **4**:1152-1156.

Nozulak J, Kalkman HO, Floersheim P, Hoyer D, Buerki HR (1995). (+)-cis-4,5,7a,8,9,10,11a-octahydro-7H-10-methyl-iondolo[1,7-bc][2,6]naphthyridine (SDZ SER 082), a centrally acting 5-HT<sub>2C</sub> receptor antagonist with low 5-HT<sub>2A</sub> receptor affinity. *J Med Chem*, **38**: 28-33.

O'Neill MF, Heron-Maxwell CL, Shaw G (1999) 5-HT<sub>2</sub> receptor antagonism reduces hyperactivity induced by amphetamine, cocaine, and MK-801 but not D1 agonist C-APB. *Pharmacol Biochem Behav* **63**:237-243.

Palacios JM, Markstein R, Pazos A (1986) Serotonin-1C sites in the choroid plexus are not linked in a stimulatory or inhibitory way to adenylate cyclase. *Brain Res* **380**:151-154.

Palacios JM, Waeber C, Mengod G, Hoyer D (1990) Visualization of serotonin receptor binding and their messenger RNAs in the mammalian brain: an update. Serotonin: From cell biology to pharmacology and therapeutics. R Paoletti et al, Eds. Kluwer Academic Publishers. pp 383-387.

Palacios JM, Pazos A, Hoyer D (2010). The making of the 5-HT<sub>2C</sub> receptor. In: Di Matteo V., Esposito E., Di Giovanni G (eds). *The Pathophysiology of Central 5-HT<sub>2C</sub> Receptors*, Springer Humana Press. DOI 10.1007/978-1-60761-941-3\_1.

Parker LL, Backstrom JR, Sanders-Bush E, Shieh BH (2003) Agonist-induced phosphorylation of the serotonin 5-HT<sub>2C</sub> receptor regulates its interaction with multiple PDZ protein 1. *J Biol Chem* **278**:21576-21583.

Parsons LH, Justice JB, Jr. (1993) Perfusate serotonin increases extracellular dopamine in the nucleus accumbens as measured by in vivo microdialysis. *Brain Res* **606**:195-199.

Parsons LH, Koob GF, Weiss F (1995) Extracellular serotonin is decreased in the nucleus accumbens during withdrawal from cocaine self-administration. *Behav Brain Res* **73**:225-228.

Patkar AA, Mannelli P, Peindl K, Hill KP, Gopalakrishnan R, Berrettini WH (2006) Relationship of disinhibition and aggression to blunted prolactin response to meta-chlorophenylpiperazine in cocaine-dependent patients. *Psychopharmacology (Berl)* **185**:123-132.

Pazos A, Palacios JM (1985) Quantitative autoradiographic mapping of serotonin receptors in the rat brain. I. Serotonin-1 receptors. *Brain Res* **346**:205-230.

Pazos A, Cortes R, Palacios JM (1985) Quantitative autoradiographic mapping of serotonin receptors in rat brain. II. Serotonin-2 receptors. *Brain Res* **346**:231-249.

Pazos A, Hoyer D, Palacios JM (1984a) The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site. *Eur J Pharmacol* **106**:539-546.

Pazos A, Hoyer D, Palacios JM, (1984b) Mesulergine, a selective serotonin-2 ligand in the rat cortex, does not label these receptors in porcine and human cortex: evidence for species differences in brain serotonin-2 receptors. *Eur J Pharmacol* **106**: 531-538.

Pazos A, Probst A, Palacios JM, (1987a) Serotonin receptors in the human brain--III. Autoradiographic mapping of serotonin-1 receptors. *Neuroscience* **21**: 97-122.

Pazos A, Probst A, Palacios JM, (1987b) Serotonin receptors in the human brain. IV. Autoradiographic mapping of serotonin-2 receptors. *Neurosci.* **21**: 123-139.

Pedigo NW, Yamamura HI, Nelson DL, (1981) Discrimination of multiple [<sup>3</sup>H]5-hydroxytryptamine-binding sites by the neuroleptic spiperone in rat brain. *J.Neurochem.* **36**: 220-226.

Pelloux Y, Dilleen R, Economidou D, Theobald D, Everitt BJ (2012) Reduced forebrain serotonin transmission is causally involved in the development of compulsive cocaine seeking in rats. *Neuropsychopharmacology* **37**:2505-2514.

Peroutka SJ, Snyder SH (1979) Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiperidol. *Mol Pharmacol* **16**:687-699.

Peyron C, Petit JM, Rampon C, Jouvett M, Luppi PH (1998) Forebrain afferents to the rat dorsal raphe nucleus demonstrated by retrograde and anterograde tracing methods. *Neuroscience* **82**:443-468.

Pompeiano M, Palacios JM, Mengod G (1994) Distribution of the serotonin 5-HT<sub>2</sub> receptor family mRNAs: Comparison between 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors. *Mol Brain Res* **23**:163-178.

Pooley EC, Fairburn CG, Cooper Z, Sodhi MS, Cowen PJ, Harrison PJ (2004) A 5-HT<sub>2C</sub> receptor promoter polymorphism (HTR2C - 759C/T) is associated with obesity in women, and with resistance to weight loss in heterozygotes. *American journal of medical genetics Part B, Neuropsychiatric genetics* **126B**:124-127.

Price RD, Sanders-Bush E, (2000) RNA editing of the human serotonin 5-HT<sub>2C</sub> receptor delays agonist-stimulated calcium release. *Mol Pharmacol* **58**: 859-862.

Price RD, Weiner DM, Chang MS, Sanders-Bush E (2001) RNA editing of the human serotonin 5-HT<sub>2C</sub> receptor alters receptor-mediated activation of G13 protein. *J Biol Chem* **276**:44663-44668.

Prisco S, Esposito E (1995) Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral temental area. *Br J Pharmacol* **116**:1923-1931.

Pritchett DB, Bach AW, Wozny M, Taleb O, Dal Toso R, Shih JC, Seeburg PH, (1988) Structure and functional expression of cloned rat serotonin 5HT-2 receptor. *EMBO J* **7**: 4135-4140.

Qiu J, Fang Y, Ronnekleiv OK, Kelly MJ (2010) Leptin excites proopiomelanocortin neurons via activation of TRPC channels. *J Neurosci* **30**:1560-1565.

Qiu J, Xue C, Bosch MA, Murphy JG, Fan W, Ronnekleiv OK, Kelly MJ (2007) Serotonin 5-hydroxytryptamine<sub>2C</sub> receptor signaling in hypothalamic proopiomelanocortin neurons: role in energy homeostasis in females. *Mol Pharmacol* **72**:885-896.

Rausser L, Savage JE, Meltzer HY, Roth BL (2001) Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. *J Pharmacol Exp Ther* **299**:83-89.

Reynolds GP, Templeman LA, Zhang ZJ (2005) The role of 5-HT<sub>2C</sub> receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* **29**:1021-1028.

Reynolds GP, Zhang Z, Zhang X (2003) Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain. *Am J Psychiatry* **160**:677-679.

Rezvani AH, Cauley MC, Levin ED (2014) Lorcaserin, a selective 5-HT(2C) receptor agonist, decreases alcohol intake in female alcohol preferring rats. *Pharmacol Biochem Behav* **125**:8-14.

Rippberger H, van Gaalen MM, Schwarting RK, Wöhr M (2015) Environmental and Pharmacological Modulation of Amphetamine- Induced 50-kHz Ultrasonic Vocalizations in Rats. *Curr Neuropharmacol* **13**:220-232.

Rocha B, DiScala G, Rigo M, Hoyer D, Sandner G (1993). Effects of 5,7-dihydroxytryptamine (5,7-DHT) lesion on mianserin-induced conditioned place aversion and 5-HT<sub>1C</sub> receptors in the rat brain. *Neuroscience*, **56**: 687-693.

Rocha B, Rigo M, DiScala G, Sandner G, Hoyer D (1994). Acute and chronic treatments by mianserin and eltoprazine in rats: effects on the elevated-plus maze and on 5-HT<sub>1C</sub> receptors in the amygdala. *Eur J Pharmacol*, **262**: 125-131.

Rocha BA, Goulding EH, O'Dell LE, Mead AN, Coufal NG, Parsons LH, Tecott LH (2002) Enhanced locomotor, reinforcing, and neurochemical effects of cocaine in serotonin 5-hydroxytryptamine 2C receptor mutant mice. *J Neurosci* **22**:10039-10045.

Rosenzweig-Lipson S, Comery TA, Marquis KL, Gross J, Dunlop J (2012) 5-HT<sub>2C</sub> agonists as therapeutics for the treatment of schizophrenia. *Handbook of experimental pharmacology*:147-165.

Rosenzweig-Lipson S, Dunlop J, Marquis KL (2007a) 5-HT<sub>2C</sub> receptor agonists as an innovative approach for psychiatric disorders. *Drug News Perspect* **20**:565-571.

Rosenzweig-Lipson S, Sabb A, Stack G, Mitchell P, Lucki I, Malberg JE, Grauer S, Brennan J, Cryan JF, Sukoff Rizzo SJ, Dunlop J, Barrett JE, Marquis KL (2007b) Antidepressant-like effects of the novel, selective, 5-HT<sub>2C</sub> receptor agonist WAY-163909 in rodents. *Psychopharmacology (Berl)* **192**:159-170.

Roth BL (2007) Drugs and valvular heart disease. *N Engl J Med* **356**:6-9.

Ruedi-Bettschen D, Spealman RD, Platt DM (2015) Attenuation of cocaine-induced reinstatement of drug seeking in squirrel monkeys by direct and indirect activation of 5-HT<sub>2C</sub> receptors. *Psychopharmacology (Berl)* **232**:2959-2968.

Rueter SM, Dawson TR, Emeson RB (1999) Regulation of alternative splicing by RNA editing. *Nature* **399**:75-80.

Saltzman AG, Morse B, Whitman MM, Ivanshchenko Y, Jaye M, Felder S (1991) Cloning of the human serotonin 5-HT<sub>2</sub> and 5-HT<sub>1C</sub> receptor subtypes. *Biochem Biophys Res Commun* **181**:1469-1478.

Schellekens H, De Francesco PN, Kandil D, Theeuwes WF, McCarthy T, van Oeffelen WE, Perello M, Giblin L, Dinan TG, Cryan JF (2015) Ghrelin's Orexigenic Effect Is Modulated via a Serotonin 2C Receptor Interaction. *ACS Chem Neurosci* **6**:1186-1197.

Schoeffter P, Waeber C, Palacios JM, Hoyer D (1988). The serotonin 5-HT<sub>1D</sub> receptor subtype is negatively coupled to adenylate cyclase in calf substantia nigra. *Naunyn Schmiedeberg's Arch Pharmacol*, **337**: 602-608.

Schoeffter P, Hoyer D, (1989) 5-Hydroxytryptamine 5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors mediating inhibition of adenylate cyclase activity. Pharmacological comparison with special reference to the effects of yohimbine, rauwolscine and some beta-adrenoceptor antagonists. *Naunyn Schmiedeberg's Arch Pharmacol* **340**: 285-292.

Serrats J, Mengod G, Cortes R (2005) Expression of serotonin 5-HT<sub>2C</sub> receptors in GABAergic cells of the anterior raphe nuclei. *J Chem Neuroanat* **29**:83-91.

Sevy S, Brown S-L, Wetzler S, Kotler M, Molcho A, Plutchik R, Van Praag HM (1994) Effects of alprazolam on increases in hormonal and anxiety levels induced by meta-chlorophenylpiperazine. *Psychiatry Res* **53**:219-229.



Shen JH, Zhao Y, Rosenzweig-Lipson S, Popp D, Williams JB, Giller E, Detke MJ and Kane JM (2014) A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia. *J Psychiatr Res* **53**:14-22.

Shen M, Bellaousov S, Hiller M, de La Grange P, Creamer TP, Malina O, Sperling R, Mathews DH, Stoilov P, Stamm S (2013) Pyrvinium pamoate changes alternative splicing of the serotonin receptor 2C by influencing its RNA structure. *Nucleic Acids Res* **41**:3819-3832.

Shepherd JK, Grewal SS, Fletcher A, Bill DJ, Dourish CT (1994) Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety. *Psychopharmacology (Berl)* **116**:56-64.

Siuciak JA, Chapin DS, McCarthy SA, Guanowsky V, Brown J, Chiang P, Marala R, Patterson T, Seymour PA, Swick A, Iredale PA (2007) CP-809,101, a selective 5-HT<sub>2C</sub> agonist, shows activity in animal models of antipsychotic activity. *Neuropharmacology* **52**:279-290.

Smith SR, Prosser WA, Donahue DJ, Morgan Me, Anderson CM, Shanahan WR, Group S (2009) Lorcaserin (APD356), a selective 5-HT<sub>2C</sub> agonist, reduces body weight in obese men and women. *Obesity(SilverSpring)* **17**:494-503.

Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, Bays H, Shanahan WR (2010) Multicenter, placebo-controlled trial of lorcaserin for weight management. *N Engl J Med* **363**:245-256.

Sodhi MS, Burnet PW, Makoff AJ, Kerwin RW, Harrison PJ, (2001) RNA editing of the 5-HT<sub>2C</sub> receptor is reduced in schizophrenia. *Mol.Psychiatry* **6**: 373-379.

Sodhi MSK, Airey DC, Lambert W, Burnet PWJ, Harrison PJ, Sanders-Bush E (2005) A Rapid New Assay to Detect RNA Editing Reveals Antipsychotic-Induced Changes in Serotonin-2C Transcripts. *Mol Pharmacol* **68**:711-719.

Somerville EM, Horwood JM, Lee MD, Kennett GA, Clifton PG (2007) 5-HT<sub>2C</sub> receptor activation inhibits appetitive and consummatory components of feeding and increases brain c-fos immunoreactivity in mice. *Eur J Neurosci* **25**:3115-3124.

Southwick SM, Krystal JH, Bremner JD, Morgan CA, 3rd, Nicolaou AL, Nagy LM, Johnson DR, Heninger GR, Charney DS (1997) Noradrenergic and serotonergic function in posttraumatic stress disorder. *Arch Gen Psychiatry* **54**:749-758.

Stam NJ, Vanderheyden P, Van Alebeek C, Klomp J, De Boer T, Van Delft AML, Olijve W (1994) Genomic organisation and functional expression of the gene encoding the human serotonin 5-HT<sub>2C</sub> receptor. *Eur J Pharmacol Mol Pharmacol* **269**:339-348.

Steed E, Jones CA, McCreary AC (2011) Serotonergic involvement in methamphetamine-induced locomotor activity: a detailed pharmacological study. *Behav Brain Res* **220**:9-19.

Strong PV, Christianson JP, Loughridge AB, Amat J, Maier SF, Fleshner M, Greenwood BN (2011) 5-hydroxytryptamine 2C receptors in the dorsal striatum mediate stress-induced interference with negatively reinforced instrumental escape behavior. *Neuroscience* **197**:132-144.

Strong PV, Greenwood BN, Fleshner M (2009) The effects of the selective 5-HT(2C) receptor antagonist SB 242084 on learned helplessness in male Fischer 344 rats. *Psychopharmacology (Berl)* **203**:665-675.

Sullivan LC, Clarke WP, Berg KA (2015) Atypical antipsychotics and inverse agonism at 5-HT2 receptors. *Curr Pharm Des* **21**:3732-3738.

Swinford-Jackson SE, Anastasio NC, Fox RG, Stutz SJ, Cunningham KA (2016) Incubation of cocaine cue reactivity associates with neuroadaptations in the cortical serotonin (5-HT) 5-HT2C receptor (5-HT2CR) system. *Neuroscience* **324**:50-61.

Tecott LH, Abdallah L, 2003 Mouse genetic approaches to feeding regulation: serotonin 5-HT2C receptor mutant mice. *CNS.Spectr.* 8: 584- 588.

Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, Julius D (1995) Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. *Nature* **374**:542-546.

Templeman LA, Reynolds GP, Arranz B, San L (2005) Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. *Pharmacogenet Genomics* **15**:195-200.

Thomas JM, Dourish CT, Tomlinson JW, Hassan-Smith Z, Higgs S (2014) Effects of the 5-HT2C receptor agonist meta-chlorophenylpiperazine on appetite, food intake and emotional processing in healthy volunteers. *Psychopharmacology (Berl)* **231**:2449-2459.

Thomsen WJ, Grottick AJ, Menzaghi F, Reyes-Saldana H, Espitia S, Yuskin D, Whelan K, Martin M, Morgan M, Chen W, Al-Shamma H, Smith B, Chalmers D, Behan D (2008) Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. *J Pharmacol Exp Ther* **325**:577-587.

Tomkins DM, Joharchi N, Tampakeras M, Martin JR, Wichmann J, Higgins GA (2002) An investigation of the role of 5-HT(2C) receptors in modifying ethanol self-administration behaviour. *Pharmacol Biochem Behav* **71**:735-744.

Tsai SJ, Hong CJ, Yu YW, Lin CH (2002) -759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain. *Lancet* **360**:1790.

van de Kar LD, Lorens SA (1979) Differential serotonergic innervation of individual hypothalamic nuclei and other forebrain regions by the dorsal and median midbrain raphe nuclei. *Brain Res* **162**:45-54.

Venzi M, David F, Bellet J, Cavaccini A, Bombardi C, Crunelli V, Di Giovanni G (2016) Role for serotonin<sub>2A</sub> (5-HT<sub>2A</sub>) and 2C (5-HT<sub>2C</sub>) receptors in experimental absence seizures. *Neuropharmacology* **108**:292-304.

Vickers SP, Clifton PG, Dourish CT, Tecott LH (1999) Reduced satiating effect of *d*-fenfluramine in serotonin 5-HT<sub>2C</sub> receptor mutant mice. *Psychopharmacology* **143**:309-314.

Voigt JP, Fink H (2015) Serotonin controlling feeding and satiety. *Behav Brain Res* **277**:14-31.

Wacker D, Wang C, Katritch V, Han GW, Huang XP, Vardy E, *et al.* (2013). Structural Features for Functional Selectivity at Serotonin Receptors. *Science* **340**: 615-619.

Wade JM, Juneja P, MacKay AW, Graham J, Havel PJ, Tecott LH, Goulding EH (2008) Synergistic impairment of glucose homeostasis in *ob/ob* mice lacking functional serotonin 2C receptors. *Endocrinology* **149**:955-961.

Waeber C, Dixon K, Hoyer D, Palacios JM (1988). Localization by autoradiography of neuronal 5-HT<sub>3</sub> receptors in mouse CNS. *Eur J Pharmacol*, **151**: 351-352.

Wallace TJ, Zai CC, Brandl EJ, Muller DJ (2011) Role of 5-HT(2C) receptor gene variants in antipsychotic-induced weight gain. *Pharmacogenomics and personalized medicine* **4**:83-93.

Wang B, Chehab FF (2006) Deletion of the serotonin 2c receptor from transgenic mice overexpressing leptin does not affect their lipodystrophy but exacerbates their diet-induced obesity. *Biochem Biophys Res Commun* **351**:418-423.

Wang Q, O'Brien PJ, Chen CX, Cho DS, Murray JM, Nishikura K (2000) Altered G protein-coupling functions of RNA editing isoform and splicing variant serotonin<sub>2C</sub> receptors. *J Neurochem* **74**:1290-1300.

Wang Y, Joharchi N, Fletcher PJ, Sellers EM, Higgins GA (1995) Further studies to examine the nature of dexfenfluramine- induced suppression of heroin self-administration. *Psychopharmacology (Berl)* **120**:134-141.

Wang C, Jiang Y, Ma J, Wu H, Wacker D, Katritch V, Han GW, Liu W, Huang XP, Vardy E, McCorvy JD, Gao X, Zhou E, Melcher K, Zhang C, Bai F, Yang H, Yang L, Jiang H, Roth BL, Cherezov V, Stevens RC, Xu H. Structural Basis for Molecular Recognition at Serotonin Receptors. *Science* **2013**, **340**, 610-614.

Watanabe Y, Yoshimoto K, Tatebe H, Kita M, Nishikura K, Kimura M, Tanaka M (2014) Enhancement of alcohol drinking in mice depends on alterations in RNA editing of serotonin 2C receptors. *The international journal of neuropsychopharmacology* **17**:739-751.

Werry TD, Gregory KJ, Sexton PM, Christopoulos A (2005) Characterization of serotonin 5-HT<sub>2C</sub> receptor signaling to extracellular signal-regulated kinases 1 and 2. *J Neurochem* **93**:1603-1615.

Werry TD, Stewart GD, Crouch MF, Watts A, Sexton PM, Christopoulos A (2008) Pharmacology of 5HT<sub>2C</sub> receptor-mediated ERK1/2 phosphorylation: agonist-specific activation pathways and the impact of RNA editing. *Biochem Pharmacol* **76**:1276-1287.

Winstanley CA, Theobald DE, Dalley JW, Glennon JC, Robbins TW (2004) 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptor antagonists have opposing effects on a measure of impulsivity: interactions with global 5-HT depletion. *Psychopharmacology (Berl)* **176**:376-385.

Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR (1999) Novel antipsychotics: comparison of weight gain liabilities. *J Clin Psychiatry* **60**:358-363.

Wohr M, Rippberger H, Schwarting RK, van Gaalen MM (2015) Critical involvement of 5-HT<sub>2C</sub> receptor function in amphetamine-induced 50-kHz ultrasonic vocalizations in rats. *Psychopharmacology (Berl)* **232**:1817-1829.

Wood MD, Reavill C, Trail B, Wilson A, Stean T, Kennett GA, Lightowler S, Blackburn TP, Thomas D, Gager TL (2001) SB-243213; a selective 5-HT<sub>2C</sub> receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety. *Neuropharmacology* **41**:186-199.

Wu X, Pang G, Zhang YM, Li G, Xu S, Dong L, Stackman RW, Jr. and Zhang G (2015) Activation of serotonin 5-HT<sub>2C</sub> receptor suppresses behavioral sensitization, naloxone-precipitated withdrawal symptoms in heroin-treated mice. *Neurosci Lett* **607**:23-28.

Xie EZ, Zhu LY, Zhao LY, Chang LS (1996) The human serotonin 5-HT<sub>2C</sub> receptor: Complete cDNA, genomic structure, and alternatively spliced variant. *Genomics* **35**:551-561.

Xu Y, Berglund ED, Sohn JW, Holland WL, Chuang JC, Fukuda M, Rossi J, Williams KW, Jones JE, Zigman JM, Lowell BB, Scherer PE, Elmquist JK (2010) 5-HT<sub>2CRs</sub> expressed by pro-opiomelanocortin neurons regulate insulin sensitivity in liver. *Nat Neurosci* **13**:1457-1459.

Xu Y, Jones JE, Kohno D, Williams KW, Lee CE, Choi MJ, Anderson JG, Heisler LK, Zigman JM, Lowell BB, Elmquist JK (2008) 5-HT<sub>2CRs</sub> expressed by pro-opiomelanocortin neurons regulate energy homeostasis. *Neuron* **60**:582-589.

Yamashita PS, de Bortoli VC, Zangrossi H, Jr. (2011) 5-HT<sub>2C</sub> receptor regulation of defensive responses in the rat dorsal periaqueductal gray. *Neuropharmacology* **60**:216-222.

Yan C, Yang Y, Saito K, Xu P, Wang C, Hinton AO, Jr., Yan X, Wu Q, Tong Q, Elmquist JK, Fukuda M, Xu Y (2015) Meta-chlorophenylpiperazine enhances leptin sensitivity in diet-induced obese mice. *Br J Pharmacol* **172**:3510-3521.

Yang W, Wang Q, Kanos SJ, Murray JM, Nishikura K (2004) Altered RNA editing of serotonin 5-HT<sub>2C</sub> receptor induced by interferon: implications for depression associated with cytokine therapy. *Brain Res Mol Brain Res* **124**:70-78.

Yoshimoto K, Watanabe Y, Tanaka M, Kimura M (2012) Serotonin<sub>2C</sub> receptors in the nucleus accumbens are involved in enhanced alcohol-drinking behavior. *Eur J Neurosci* **35**:1368-1380.

Yu L, Nguyen H, Le H, Bloem LJ, Kozak CA, Hoffman BJ, Snutch TP, Lester HA, Davidson N, Lübbert H (1991) The mouse 5-HT<sub>1C</sub> receptor contains eight hydrophobic domains and is X-linked. *Mol Brain Res* **11**:143-149.

Yuan X, Yamada K, Ishiyama-Shigemoto S, Koyama W, Nonaka K (2000) Identification of polymorphic loci in the promoter region of the serotonin 5-HT<sub>2C</sub> receptor gene and their association with obesity and Type II diabetes. *Diabetologia* **43**:373-376.

Zhang G, Wu X, Zhang YM, Liu H, Jiang Q, Pang G, Tao X, Dong L, Stackman RW, Jr. (2016) Activation of serotonin 5-HT<sub>2C</sub> receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in morphine-dependent mice. *Neuropharmacology* **101**:246-254.

Zhou L, Sutton GM, Rochford JJ, Semple RK, Lam DD, Oksanen LJ, Thornton-Jones ZD, Clifton PG, Yueh CY, Evans ML, McCrimmon RJ, Elmquist JK, Butler AA, Heisler LK (2007) Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways. *Cell Metab* **6**:398-405.

Zhu H, Urban DJ, Blashka J, McPheeters MT, Kroeze WK, Mieczkowski P, Overholser JC, Jurjus GJ, Dieter L, Mahajan GJ, Rajkowska G, Wang Z, Sullivan PF, Stockmeier CA, Roth BL (2012) Quantitative analysis of focused A-to-I RNA editing sites by ultra-high-throughput sequencing in psychiatric disorders. *PLoS One* **7**:e43227.

**TABLE 1: Important preclinical and clinical developments in and around the 5-HT<sub>2C</sub> receptor field.**



1948	Synthesis of 5-HT	Rapport, 1948
1957	5-HT <sub>M</sub> and 5-HT <sub>D</sub> receptors in guinea pig ileum	Gaddum and Picarelli, 1957
1978	Concept of neuroleptic receptor	Leysen et al. 1978
1979	Concept of 5-HT <sub>1</sub> and 5-HT <sub>2</sub> sites in brain	Peroutka and Snyder, 1979
1981	5-HT <sub>1A</sub> and 5-HT <sub>1B</sub> binding	Pedigo et al. 1981
1982-	8-OH-DPAT, a selective 5-HT <sub>1A</sub> agonist and radioligand	HJorth et al. 1982; Middlemiss and Fozard, 1983; Gozlan et al. 1983
1983	[ <sup>3</sup> H]Mesulergine, a dopaminergic ligand labels 5-HT <sub>2</sub> sites	Closse, 1983
1984-	The choroid plexus receptor defined as 5-HT <sub>1C</sub> receptor using [ <sup>3</sup> H]mesulergine, [ <sup>3</sup> H]5-HT, [ <sup>125</sup> I]LSD and [ <sup>125</sup> I]SCH23982	Pazos et al. 1984a; 1984b; Hoyer et al. 1985a; 1985b; Yagaloff and Hartig; 1985; 1986; Hoyer and Karpf, 1988
1985	Full characterization of 5-HT <sub>1A</sub> , 5-HT <sub>1B</sub> , 5-HT <sub>1C</sub> receptors (species differences, no 5-HT <sub>1B</sub> in pig brain), comparative distribution of 5-HT <sub>1</sub> /5-HT <sub>2</sub> sites in rodent brain	Hoyer et al. 1985a, 1985b; Pazos and Palacios, 1985; Pazos et al. 1985
1986-	Distribution of 5-HT <sub>1</sub> and 5-HT <sub>2</sub> receptors in the brain (species differences, no 5-HT <sub>1B</sub> sites in human brain)	Hoyer et al. 1986a; 1986b
	Cloning of the beta <sub>2</sub> adrenoceptor and 5-HT <sub>1A</sub> receptor (the orphan G21)	Dixon et al. 1986; Fargin et al. 1988
	5-HT <sub>1C</sub> couples to PLC activity, does not couple to cAMP production	Conn et al. 1986; Palacios et al. 1986, Hoyer et al. 1989
1987	Partial cloning of 5-HT <sub>1C</sub> receptor	Lubbert et al. 1987
1988-	5-HT <sub>1C</sub> and 5-HT <sub>2</sub> receptors proposed to belong to same family based on pharmacological/operational and 2 <sup>nd</sup> messengers/transductional criteria	Hoyer 1988a, 1988b
	Full length cloning of 5-HT <sub>1C</sub> and 5-HT <sub>2</sub> receptors	Julius et al. 1988; Pritchett et al. 1988; Saltzmann et al. 1991; Xie et al. 1996
	5-HT <sub>1D</sub> site identified in non-rodent brain	Hoyer et al. 1988; Waeber et al. 1988; Hoyer et al. 1988
1989-	Structural similarities between 5-HT <sub>2A</sub> and 5-HT <sub>1C</sub> receptors	Julius et al. 1989; Foguet et al. 1992b
	In situ hybridization of 5-HT <sub>1C</sub> R mRNA in brain	Hofman and Mezey 1989; Mengod et

		al. 1990; Palacios et al. 1990; Pompeiano et al. 1994; Lopez-Gimenez et al. 2001; Serrats et al. 2005; Mengod et al. 2010
	5-HT <sub>1B</sub> and 5-HT <sub>1D</sub> receptors may be species homologues?	Hoyer and Middlemiss, 1989
1992	Structural similarities between the 5-HT <sub>2F</sub> receptor (fundus) and 5-HT <sub>2</sub> and 5-HT <sub>1C</sub>	Foguet et al. 1992b; Lubbert et al. 1992
1993-	New nomenclature proposal for 5-HT receptors: 5-HT <sub>1C</sub> becomes 5-HT <sub>2C</sub> , 5-HT <sub>2</sub> = 5-HT <sub>2A</sub> , 5-HT <sub>2F</sub> = 5-HT <sub>2B</sub> , 7 families are recognised	Humphrey et al. 1993
	Role of 5-HT <sub>2C</sub> receptors in the amygdala / fear / aversion / anxiety / depression	Rocha et al. 1993; 1994; Cryan and Lucki, 2000; Millan, 2003; 2005; Rosenzweig Lipson et al. 2007b
1994	Official IUPHAR nomenclature 5-HT receptors	Hoyer et al. 1994
1995-	5-HT <sub>2C</sub> R KO mice show feeding / metabolic defects, hyperphagia, late-onset obesity, insulin resistance, type 2 diabetes, epileptic seizures, an addiction phenotype, locomotor hyperactivity, neuroendocrine response to stress, anxiolytic phenotype.	Tecott et al. 1995; Brennan et al. 1997; Nonogaki et al. 1998; Vickers et al. 1999; Heisler and Tecott 2000; Tecott and Abdallah, 2003; Heisler et al., 2007a; 2007b; Wade et al. 2008; Tecott et al. 2005; Xu et al. 2008; 2010
	Synthesis of selective 5-HT <sub>2C</sub> R antagonists, inverse agonists: SDZ SER082, SB 206553; SB-242084, RS-102221, SB2 43213, FR260010,	Nozulak et al. 1995; Kenneth et al. 1996; Bromidge et al. 1997; Bonhaus et al. 1997; Wood et al. 2001; Harada et al. 2006.
	Brain distribution of 5-HT <sub>2C</sub> R using Antibodies	Abramowski et al. 1995
1996-	5-HT receptors aligned to human genome, 5-HT <sub>1D</sub> alpha/beta become 5-HT <sub>1B</sub> and 5-HT <sub>1D</sub>	Hartig et al. 1996; Hoyer and Martin, 1997
1997-	5-HT <sub>2C</sub> R is unique amongst GPCRs and subjected to multiple RNA editing. The unedited INI and the fully edited (VSV and VGV) isoforms show high and low constitutive activity.	Burns et al. 1997; Niswender et al. 1999; 2001; Rueter et al. 1999; Fitzgerald et al. 1999; see also Dracheva et al. 2003; 2008a; 2008b; 2009; Camel et al. 2012; Du et al. 2006; 2007; Di Narzo et al 2014; 2015
1999-	Many antipsychotics are 5-HT <sub>2C</sub> R inverse agonists/ antagonists. May explain obesity produced by antipsychotics.	Berg et al. 1999; Sullivan et al. 2015; Tsai et al. 2002; Templeman et al. 2005; Wallace et al. 2011

	The 5-HT <sub>2B</sub> R is responsible for valvulopathies induced by agonists: fenfluramine, norfenfluramine, valproex, MDMA. 5-HT <sub>2B</sub> R agonists are withdrawn from the market (fenfluramine, norfenfluramine, cabergoline, pergolide, valproex). Strict limitations for the development of 5-HT <sub>2</sub> R agonists.	Rothmann et al. 2000; Setola et al. 2003; Roth, 2007; Huang et al. 2009; Rothmann and Baumann, 2009a, 2009b
2002-	5-HT <sub>2C</sub> R agonism in nicotine, cocaine and alcohol addiction	Rocha et al. 2002; Filip and Cunningham, 2002; Tomkins et al. 2002; Bubar and Cunningham, 2006; 2007; 2008; Cunningham et al. 2011; 2013; 2014; Liu et al. 2011; 2012; Levin et al. 2011; Higgins et al. 2012; Rezvani et al. 2014; Anastasio et al. 2014, 2015
2003-	Agomelatine, the first 5-HT <sub>2C</sub> R antagonist / melatonin R agonist in development for major depressive disorders	Millan et al. 2003; Millan, 2005; Millan et al. 2005;
2004-	5-HT <sub>2C</sub> R Homomers, dimers; 5-HT <sub>2C</sub> R/NMDAR heteromer; 5-HT <sub>2C</sub> R /ghrelin receptor heteromer; 5-HT <sub>2C</sub> R/melatonin MT <sub>2</sub> R heteromer	Herrick-Davis et al. 2004, 2006, 2011, 2012, 2013; Bigford et al., 2012; Schellenkens et al. 2015; Kamal et al. 2015
2005-	Agomelatine: submission to EMEA for major depressive disorders; EMEA rejects agomelatine.	See EMEA/37021/2007
2005-	Discovery of 5-HT <sub>2C</sub> R Agonists: WAY-163909; Vabicaserin (SCA136), Lorcaserin (APD356)	Dunlop et al. 2005; 2011; Thomsen et al. 2008
2007-	5-HT <sub>2C</sub> R agonist vabicaserin (Pfizer); inverse agonists e.g. Sertindole; Development in schizophrenia	Siuciak et al. 2007; Dunlop et al. 2006; Rosenzweig-Lipson 2007a, 2012; Shen et al. 2014
2008-	Lorcaserin submitted to FDA for obesity	Thomsen et al. 2008; Smith et al. 2009; 2010; Higgs et al. 2016
2009	EMEA approves agomelatine as Valdoxan®, Melitor®, Thymanax® by Servier.	See EMA/633676/2014 (valdoxan), see EMA/695134/2016 (Thymanax)
2010-	5-HT <sub>2C</sub> receptors in spinal cord injury, increased editing and constitutive activity, role in muscle spasms	Murray et al. 2010; Fouad et al. 2010; Murray et al. 2011; Husch et al. 2012
2012	FDA approves Lorcaserin for the treatment of certain forms of obesity as Belviq®, co-development between Arena and Eisai.	See FDA (2012)

2013-	Regular IUPHAR receptor Nomenclature updates in BJP	Alexander et al. 2013; 2015
	Crystal structure of 5-HT <sub>1B</sub> and 5-HT <sub>2B</sub> receptors reveals striking similarities in orthosteric binding sites, yet profound pharmacological differences.	Wacker et al. 2013; Wang et al. 2013; McCorvy and Roth, 2015
2014	Lorcaserin is active in nicotine addiction	See Eisai (2014)
	Development of vabicaserin in schizophrenia is stopped by Pfizer	See GovtTrials (2014)
2016	5-HT <sub>2C</sub> R agonism effective in oxycodone abuse (rodents)	Cunningham et al. 2016